Ten year audit of cancer care at St. James’s Hospital 2003-2012. by unknown
Ten year CanCer audiT reporT 
ST. JameS’S HoSpiTal
2003–2012
O
sp
idé
al Naomh Séam
as
Seirbhís Dé agus A
 P
ho
ba
il
10
Compiled by: 
Cancer audit programme Team, St. James’s Hospital.
Table of Contents
Foreword 2
In Memory 3
Objective 4
Background 5
Executive Summary 6
Section 1: General Aspects of Cancer Audit 9
1.1  Demographic Data 11
1.2  Multidisciplinary Team (MDT) Meeting 14
1.3  Systemic Therapy 15
1.4  Radiation Oncology 17
1.5  Surgical Oncology 18
1.6  Palliative Care 19
1.7  Cancer Clinical Trials Office (CCTO) 21
1.8  Cancer Genetics Service 22
1.9  Psycho-Oncology 24
1.10  Allied Health Services 25
1.11  Diagnostic Radiology 31
1.12  Histopathology 34
1.13  Cancer Research 36
Section 2: Site Specific Cancer Audit 39
2.1  Lung Cancer 41
2.2a  Oesophageal and Oesophago-gastric Junction 48
2.2b  Gastric Cancer (excluding junctional) 52
2.3  Skin Cancer 55
2.4  Head & Neck Cancer  60
2.5  Colorectal Cancer 62
2.6  Gynaecological Cancer 68
2.7  Urology Cancer 74
2.8  Haematological Malignancies 82
2.9  Breast Cancer 87
Appendix 1 Methods 93
Appendix 2 Cancer Audit Programme Team 95
Appendix 3 References 96
Appendix 4 Audit Publications 97
Appendix 5 Abbreviations 99
Appendix 6 Acknowledgements 103
2Foreword
It gives me great pleasure to contribute a foreword to this Ten Year Audit 
of Cancer Care at St. James’s Hospital. This report complements our 
previous six year report. The report enables us to benchmark ourselves 
against National and International standards in a very substantive way.
Safe and efficient cancer care relies on high 
quality data. By taking responsibility for our 
clinical data, clinicians can only improve the 
quality of care and help enhance standards. We 
have developed structures and processes for the 
measuring and monitoring of the quality of care, 
using a core set of performance indicators and 
comprehensive datasets. 
The Hospital Cancer Audit Program is long 
established at St. James’s. The objectives of 
the program are to highlight patient volumes, 
complexity of treatment, trends & referral 
patterns and ultimately the quality of care 
provided. We are committed to high quality data 
collection, statistical analysis and reporting. Our 
goal is the continuous re-evaluation of our data 
against the findings of this audit and the move 
to a more robust platform of information capture 
through more efficient electronic data capture.
During the ten year period, St James’s Hospital 
diagnosed and/or treated almost 29,000 new 
cancer patients, representing 12% of national 
cancer activity. It should be noted that this 
represents a 97% local workload increase over 
the last ten years. The data is now sufficiently 
mature to provide a basis for long term outcome 
analysis. This type of report is unique in Ireland 
and represents a positive investment in cancer 
over the last decade. 
Cancer care quality measures should:
• Span the continuum of multidisciplinary cancer 
care and be developed through a coordinated 
effort:
• Be used to hold providers accountable for 
demonstrating that they provide and improve 
quality of care;
• Be disseminated widely and communicated 
openly and meaningfully to clinicians, our 
cancer patients and their families, managers, 
policy makers, and cancer researchers, in a 
form that is relevant and useful for health care 
decision-making.
St. James’s Hospital has been to the forefront 
of developing multidisciplinary care for cancer 
patients in this country for many years. This 
publication of our ten year cancer audit report 
is an essential element in driving quality 
improvement in cancer care. The results of this 
audit will inform all facets of our collaborative 
cancer program at the Hospital which can 
only lead to further improvements to patient 
outcomes.
I congratulate all those involved in the 
development of this audit report that helped 
create a valuable and worthwhile project 
providing information to better develop cancer 
care ensuring quality and fairness in the provision 
of services to all.
Brian Fitzgerald  
Chief Executive  
St. James’s Hospital
3In Memory
This ten year report is dedicated to the memory of our great friend 
and colleague Professor Donal Hollywood who passed away earlier this 
year at the tragically early age of 53. Donal was a towering presence 
in the development of cancer services both in St James’s Hospital and 
nationally over the past 20 years. He was appointed in 1994 to the 
Marie Curie Chair of Clinical Oncology in Trinity College Dublin and 
as a Consultant Radiation Oncologist in St. James’s and St. Lukes’s 
Hospitals. Over the past 18 years he developed a large and successful 
practice and became a driving force in the multidisciplinary care of 
cancer patients in St James’s Hospital. His achievements in research, 
teaching and the development of radiation services both on the 
national and international arenas are well documented. We remember 
a quiet, thoughtful, courteous colleague, friend and doctor who 
never failed to go the extra distance for his patients. We will miss his 
erudition, his kindness and his intellect. As we compile this report, he is 
very much in our thoughts.
ProFessor Donal HollywooD
4Objective
The primary objective of this report is to present a comprehensive audit 
of cancer care undertaken at St. James’s Hospital from 2003 to 2012, 
inclusive.  The unique dimension in the Irish context is the focus on 
outcomes of cancer care, stage by stage for each individual cancer.  
The report also includes patterns in patient volumes and incidence 
trends, referral patterns, and complexity of care. The outcome and 
process data can be used to compare against published benchmarks 
from international cancer centres or national reports.  
Audit has driven continuous quality improvement 
at St. James’s Hospital, and during this time 
period structures including multidisciplinary 
teams, defined cancer clinics, and rapid-access 
processes and care pathways, have all evolved 
to underpin the cancer programme. This audit, 
unique in the Irish context, provides information 
that allows patient’s information on institution-
specific cure rates and outcomes relevant for a 
particular cancer and stage of disease. The audit 
also enables detailed information to be provided 
to the administration and board of the hospital, 
and relevant bodies including the Department of 
Heath and Children, the Health Service Executive, 
the National Cancer Control Programme, and 
the Health Information Quality Authority. It also 
provides a framework for measuring the cost  
of cancer care.
5Background
The Cancer Audit Programme (CAP) at St. James’s Hospital was 
established in 2001. The goal is to provide comprehensive prospective 
data on the structures, processes and outcomes of cancer care provided 
by the many national, supra-regional and regional cancer programmes 
in the Hospital. Information on outcomes for all cancers, broken down 
by stage of disease, is unique in the Irish context and relatively rare 
internationally. Outcome data provides information to patients, enables 
audit and continuous quality improving of services, and benchmarking 
against best international data. 
It also informs the Administration and Board of 
the Hospital, the Health Service Executive and 
the Department of Health on quality aspects 
of cancer care, and allows estimates of cost. In 
2013, the CAP is also integral to the provision 
of information to the National Cancer Control 
Programme (NCCP) and the Health Information 
and Quality Authority (HIQA). The registry 
structure also enables the research function of the 
academic centre, interfacing with translational 
and clinical cancer research, and clinical trials. 
Cancer audit structure 
The CAP is managed by a Cancer Audit Manager, 
with dedicated cancer data managers in lung, 
oesophageal/gastric, breast, haematology, 
colorectal, gynaecological and head & neck. 
Each data manager reports to both the Cancer 
Audit Manager and the clinical lead with a 
direct responsibility for each cancer. The CAP is 
clinically driven by the Cancer Audit Director with 
direct input and output to the CEO office. The 
technical function of CAP is directly supported 
by the IMS Department. The existing CAP uses 
the information system PATS (Patient Analysis 
Tracking System). There are also a number of 
other cancer registries associated with cancer care 
in the hospital, including the Breast Clinic, Rapid 
Access Prostate Clinic, Barretts Oesophagus, and 
Cancer Clinical Trials.
reporting
The first report was in 20041, followed by a six 
year report of incidence and outcome cancer data 
in 2008, the first report of its kind in Ireland2. 
One of the recent key developments within 
cancer audit in the introduction of tumour site 
specific Quality Improvement Programmes (QIP). 
One of the key aims is to monitor and improve 
each service in order to ensure the continuous 
provision of safe, effective, quality cancer care 
to its patients and community and compliance 
with all relevant legislation, regulation and both 
national and international best practice standards. 
The QIP provides a platform for validation, review 
and quality assurance of the cancer data and also 
in-house and NCCP Key Performance Indicators 
(KPI) produced by individual data managers. The 
ultimate aim of the programme is to develop a 
framework and foster a culture of continuous 
quality improvement, whereby real time data is 
reviewed regularly at an individual service level 
and findings that have been put in place to 
deliver continual improvements in the quality of 
cancer care.
1 Cancer Programme Audit Report 2004. St. James’s Hospital, 
Dublin.
2 Six-year Cancer Audit Report, St. James’s Hospital, Dublin.
6Executive Summary
• A marked increase in cancer care took place 
over this 10 year time period. In 2012, almost 
4000 new cancer patients were diagnosed and/
or treated in St. James’s Hospital. Excluding 
non-melanoma skin cancer this represents an 
approximate doubling of new cancer referrals 
over the study period.
• There has been an approximate 100% increase 
in new referrals for lung cancer, oesophageal 
cancer, stomach cancer, head and neck cancer, 
and malignant melanoma.
• Breast cancer activity has increased by 35%, 
colorectal cancer by 45%, and gynaecological 
cancer by 85%. 
• The average age of patients diagnosed and/or 
treated in SJH is 60 years .There were 14677 
women diagnosed compared with 14,144 men.
• Cancer outcomes across the spectrum of cancer 
at St. James’s Hospital compares favourably 
with international benchmarks. 
• The average cancer clinical trial involvement 
over the period is approximately 6%, with a 
peak of 16% in 2008. 
• Imaging for cancer, including MRI, CT, PET/CT 
and mammography, has doubled, from 30,000 
in 2006 to 60,000 in 2012.
• There exists cognate complex cancer surgery for 
lung, oesophageal and head and neck cancer, 
which overlap with respect to complexity of 
surgery, multidisciplinary care, integrated peri-
operative care pathways, critical care support, 
quality of life issues, and cost. These respective 
services account for between 33-53% of 
the national workload. There are also strong 
cognate links between colorectal, urological 
and gynaecological cancers. 
• Lung cancer is the highest volume cancer, 
with almost 700 new diagnoses in 2012, 
accounting for approximately 27% of the 
national workload. Less than 10% of cases are 
non-smokers, and the incidence is similar in 
current and ex-smokers. Encouragingly, 47% 
of patients have clinical stage I or stage II at 
the time of diagnosis, and can be treated with 
curative intent. 
• St. James’s Hospital was recently designated 
as the National Centre for Oesophageal and 
Gastric Cancer and the National Centre for 
Management of Early Upper Gastrointestinal 
Mucosal Neoplasia. The hospital manages 
approximately 65% of oesophageal surgical 
resections nationally. Cure rates are improving, 
with overall survival at 35%, 65% for node-
negative disease, and 75% for Stage I/
II disease, outcomes consistent with best 
international benchmarks.
• Gynaecological cancer care at St. James’s 
Hospital is designated by the NCCP as a 
regional and national referral centre for the care 
of women with genital tract malignancies. The 
service accounts for a significant percentage 
of national activity accounting for 37%, 28%, 
26%, and 20% of vulval, ovarian, cervical, 
and endometrial cancer workload, respectively, 
with a 5-year survival of 68%, 48%, 67%, and 
68%, respectively.
7• Skin cancer is the commonest cancer.  
The Dermatosurgery Unit in St. James’s 
Hospital is the only unit which provides a Mohs 
Micrographic Surgery service to public health 
patients in the Republic of Ireland requiring 
facial surgery for basal and squamous cell 
cancer. There has over a doubling of new 
diagnoses of malignant melanoma since 2003, 
with 152 patients diagnosed and managed in 
2012, and a five year survival rate of 87%.
• There has been a 2.5-fold increase in new 
urology cancers diagnosed and/or treated in 
this ten year period with a near 5-fold increase 
in prostate cancer alone. The urology service 
accounts for 14% of the national Rapid Access 
Prostate Cancer activity, with approximately 180 
new cancers diagnosed from the Rapid Access 
service annually. Over 50% of kidney cancer 
surgery is now performed laparoscopically.
• St. James’s Hospital is a high volume centre 
for colorectal diseases, with minimally invasive 
(laparoscopic) surgery the preferred approach 
within the Unit, comprising approximately 55% 
of operations performed over the last 5 years. 
There has been a 43% increase in the numbers 
of new patients over this time period. 
• St. James’s Hospital Breast Unit was designated 
as one of the eight specialist centres for 
Symptomatic Breast Disease Services in Ireland 
by the National Cancer Control Programme in 
2007. A well as managing symptomatic breast 
patients, our Unit has dedicated family risk 
clinics for screening and managing women with 
a genetic predisposition to breast cancer. The 
overall 5-year survival is approximately 80%, 
and over 90% for early stage disease. 
• The Haematology Oncology Department in 
SJH provides care for patients with general and 
malignant haematological disorders including 
leukaemia, myeloma and lymphoma. The 
service incorporates the National Adult Bone 
Marrow Transplant Unit, provides a matched 
unrelated transplant service to Northern 
Ireland and a tertiary referral for complex 
haematological malignancies to haematology 
colleagues in other units. There has been 
an increase in autologous and allogeneic 
transplants over the study period, with 84 and 
73 performed in 2012, respectively. The 5-year 
survival rates are 60% and 49%, respectively. 
• Translational cancer research is a key platform 
linking SJH and Trinity College Dublin. 
This is greatly enabled by the proximity of 
the hospital to the Trinity College cancer 
research laboratories on the same campus. 
Internationally, the move to formalise the 
translational process has led to the strategic 
formation of specialised Institutes of 
Translational Medicine. Cancer research is also 
enabled by the new Wellcome Trust-Health 
Research Board Clinical Research Building. 

1section 1: General Aspects  of Cancer Audit
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1.1 Demographic Data
Incidence
St. James’s Hospital (SJH) diagnosed and/or almost 4000 new cancers in 2012. When Non Melanoma 
Skin Cancers (NMSC) are excluded, this represents 12% of national cancer activity1. The cancer 
workload in SJH has increased significantly with a 97% increase in the overall workload in this ten-year 
period (exc, NMSC). The largest increase in activity has been seen in lung, urology, head and neck and 
melanomas (table 1.1).
Table 1.1 Cancer activity in SJH 2003-2012
Cancer Type 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
% Increase 
in activity 
in 10 years
NMSC 383 425 412 517 574 679 677 730 724 804 110%
Lung 280 302 323 348 415 394 446 512 587 648 131%
Breast 202 138 141 134 160 162 210 276 285 272 35%
Oesophagogastric 118 143 134 164 189 197 197 229 278 263 123%
Urology 128 144 203 208 216 226 318 381 448 445 246%
Colorectal 123 139 142 166 168 180 209 198 207 176 43%
Head & Neck 128 153 165 151 183 195 205 240 259 285 123%
Lymphoma 134 152 164 156 149 145 144 172 204 184 37%
Gynaecological 160 153 180 198 197 243 287 288 293 297 86%
Melanoma 68 76 69 99 105 119 139 127 163 152 124%
Hepatic/Pancreas 69 58 62 59 64 70 75 67 122 112 62%
Haematological 141 143 147 142 164 154 158 151 152 137 0%
Bone 3 3 5 4 6 9 7 6 7 8 167%
Endocrine 21 30 36 39 55 52 52 58 69 72 243%
Sarcoma 24 35 24 31 30 49 59 68 66 76 217%
Exotic/Unknown Primary 7 8 12 10 15 16 24 18 23 27 286%
Both day-case and in-patient activity from Hospital In-patient Enquiry System (HIPE) indicate a 
substantial increase in SJH to the end of 2012 (see fig 1.1/1.2).
1 Based on 2010 SJH versus National Cancer Registry (NCRI) comparisons, the latest available data from the NCRI.
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referral Details
SJH is a national referral centre for many cancers. 
Tertiary referrals are now patients from outside 
the Dublin Mid Leinster region, rather than 
outside the now redundant East Region Health 
Authority (ERHA) region. A breakdown of this is 
seen is table 1.2
Basic Demographics
Basic demographics were analysed for patients 
over the ten year period (exc. NMSC). The ratio of 
male to female is 1:1 over the ten years and there 
was little variation again across the ten years 
(table 1.3).
Table 1.3 male to Female ratio by year of diagnosis
sex 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
Female 53% 50% 51% 51% 50% 51% 52% 54% 51% 52% 51%
Male 47% 50% 49% 49% 50% 49% 48% 46% 49% 48% 49%
The average age of patients diagnosed and/or treated in SJH is 60 years [median age is 62 years].  
The median age at diagnosis was 59, range [10-103] and was significantly lower (p<0.01) in women 
across the ten year period compared to a median age of 65 in men, range [13-99] (see table 1.4).
Table 1.2 Tertiary referral rates for cancer in SJH
Cancer site referral rate
Oesophageal 53%
Lung 42%
Gastric 40%
Gynaecology 32%
Haematology malignancy 29%
Lymphoma 28%
Head & Neck 27%
Urology 25%
Melanoma 14%
Colorectal 12%
Breast 9%
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Table 1.4 median age at diagnosis  
by year
year Female Male
2003 57 64
2004 59 64
2005 60 65
2006 60 64
2007 60 65
2008 60 64
2009 58 65
2010 58 64
2011 60 66
2012 61 66
Total 59 65
32% of women were diagnosed before the age 
of 50 compared to 18% of males. 
smoking History
Smoking accounts for one in four cancer deaths, 
and nearly a fifth of all cancer cases.
Smoking is a prime cause of lung cancer but it is 
also a known risk factor in several other cancers. 
Approximately 1,500 people develop lung cancer 
each year and 90% of these cases are directly 
caused by smoking.
Table 1.5  Smoking Status by Sex
smoking History Female Male
No Smoking History 44% 26%
Smoking History 56% 74%
Smoking status remains difficult to capture, 
however it has greatly improved since the last 
report with less missing or unknown data. Where 
documented, 56% of females (table 1.5) had 
a smoking history (either current or ex-smoker) 
compared to 74% of males. The percentage 
of women smoking over the ten year period 
has risen and in particular in the last five years. 
In individual tumour sites, over 90% of lung 
cancer patients had a smoking history, as did 
61% colorectal, 64% head and neck cancers 
and 69% oesophageal cancer patients. 42% of 
gynaecological cancers had a smoking history.
Family History
Family history is recorded where available but the recording of family history has improved in the last 
five years. Any family history of cancer is recorded in table 1.6.
Table 1.6  Family History by year of diagnosis
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
25% 22% 25% 20% 19% 21% 24% 26% 21% 19%
51% of gynaecological cancers had a family history of cancer, 44% breast (29% of all breast cancers 
have a breast family history), 44% colorectal, 41% oesophageal and 35% gastric. 13% of prostate 
cancer patients had a first degree relative with prostate cancer.
14
1.2 Multidisciplinary Team 
(MDT) Meeting
overview
Eight cancer multidisciplinary team conferences 
are held weekly in SJH to establish consensus 
diagnosis and treatment plans for all cancer 
patients. All MDT conferences require expertise 
from surgery, pathology, radiology, medical and 
radiation oncology. Conferences are supported 
by an MDT co-ordinator who liaises with all 
specialties within SJH and other hospitals 
regionally and nationally.
Process
MDT is a standard of care for cancer patients in 
SJH. SJH is the super regional catchment area for 
lung, lymphoma and gastrointestinal cancers.  
The SJH team examines all diagnostic material 
sent from referring hospitals and present their 
findings via video conferencing. Medical teams 
around the country can seek the advice of  
our expert medical team in SJH and vice versa  
and produce efficient and timely care for  
cancer patients.
Cancer MDT activity
Table 1.7 demonstrates the number of patients discussed at the Cancer MDT meetings over  
the period 2005-2012.
Table 1.7 mdT activity by Tumour Site
Tumour site 2005 2006 2007 2008 2009 2010 2011 2012
Upper & Lower GI 169 429 407 837 846 1059 1167 1109
Urology 62 206 155 557 525 623 781 942
Gynae 297 465 588 814 935 1136 1158 1256
Breast 707 742 888 1469 1906 1947 2122 1935
Lung 424 821 919 1524 1297 1357 1587 1504
Head & Neck * 160 291 444 495 638 599 689
Lymphoma 177 229 214 267 228 388 387 429
Skin 495 835 718 1421 1343 1491 1599 369
* Head & Neck MDT was not in operation until 2006
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1.3 Systemic Therapy
Haematology oncology and Medical oncology activity continue to increase year on year with 27297 patients 
attending day services in oncology and haematology.
Haematology oncology
The haematology department in SJH provides care for patients with general and malignant 
haematological disorders including leukaemia, myeloma and lymphoma. The service incorporates 
the National Adult Bone Marrow transplant unit, provides a Matched Unrelated transplant service 
to Northern Ireland and a tertiary referral for complex haematological malignancies to haematology 
colleagues in other units.
*Haematology Oncology data includes coagulation figures which account for 10% of Haematology Oncology activity.
Out-patient attendances have increased significantly since 2008 for haematology oncology,  
and medical oncology increases year-on-year.
Figure 1.1 days activity for Haematology oncology/medical oncology
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*Haematology Oncology data includes coagulation figures which account for 10% of Haematology Oncology activity.
In patient activity has also increased for both medical oncology and haematology oncology with a total 
of 2427 discharges in 2012.
Medical oncology
The medical oncology service in SJH has grown 
over the past ten years in concert with the 
hospital as a whole, reflecting the emerging 
position of SJH as the largest cancer hospital in 
the country. A total of four medical oncologists 
provide specialised services to patients with the 
full range of cancers. Services are tightly aligned 
with our surgical and radiation colleagues 
through a large programme of multidisciplinary 
conferences and optimal care is facilitated by 
development of newer services such as Molecular 
Diagnostics, PET/CT scanning and on site 
radiation therapy. Specialist registrars are trained 
in the programme and large numbers of patients 
are enrolled on clinical trials. 
activity
Activity has increased enormously over the past 
10 years. Annual in-patient admissions have 
doubled from 700 to 1400 and day treatments 
have increased from 8,200 to 14,500 annually. 
Reflecting the specialist surgical oncologic 
expertise in the hospital and the centralisation of 
services nationally there have been particularly 
large increases in the numbers of patients with 
gynaecologic, lymphatic, lung, upper GI and breast 
cancers seen in the past ten years.
Developments/Innovations
With the increase in number of medical 
oncologists to four we have been able to provide 
site specialised care to patients with most 
malignancies. With the support of colleagues in 
the haematology department we have developed 
a national programme for high-dose therapy 
in patients with relapsed germ cell tumours. 
Research activities have expanded not only in the 
Clinical Trials Unit which is led by Dr. Dearbhaile 
O’ Donnell but also in the Thoracic Malignancies 
laboratory and in conjunction with Professor 
Elizabeth Connolly in the Breast Cancer  
Research Laboratories. 
The increased number of patients requires  
a larger dedicated medical oncology in-patient 
unit and we are in the process of making this 
transition. Further expansion of medical oncology 
services will only be possible with the addition of  
new consultants.
Figure 1.2 in-patient Haematology oncology and medical oncology 2003-2012
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1.4 Radiation Oncology
Patients attending SJH who require Radiotherapy 
attend St. Luke’s Radiation Oncology Network 
(SLRON) for treatment. The network operates 
from three locations - St. Luke’s Hospital (SLH), 
Rathgar, St. Luke’s Radiation Oncology Centre 
(SLROC) at SJH and SLROC at Beaumont Hospital. 
The new centres opened in March 2011 following 
an investment of 60 million euros by the NCCP. 
There are now 12 linear accelerators within the 
network resulting in faster access for patients 
requiring Radiotherapy. 
Over 4,000 patients were treated across all three 
centres in 2011. Each new centre features four 
new state of the art treatment linear accelerators 
(LA) as well as two CT scanners and one MRI 
unit. The LA’s (each representing an investment 
of well in excess of €1m) differ slightly in their 
specifications. The SJH centre houses a unit 
capable of delivering Total Body Irradiation (TBI) 
for haematology patients attending the National 
Stem Cell Transplantation Centre and in May 
2013 the TBI service was transferred from SLH  
to SJH, which is more convenient for the patients 
as the vast majority who require this form of 
treatment, are primarily in-patients in SJH. 
structure
There are six Consultant Radiation Oncologists 
that work within SLRON and provide Radiotherapy 
to SJH. They include Dr. Catriona O’Sullivan,  
Dr. Charles Gillham, Dr. Moya Cunningham,  
Dr. Sinéad Brennan, Dr. Pierre Thirion and  
Dr. Nazmy Elbeltagi. 
All consultants provide a comprehensive  
in-patient consultation and out-patient 
department (OPD) service, and collectively  
attend all the hospital’s oncology MDT meetings. 
Nursing support is provided by a Radiation 
Oncology Liaison Nurse, Ms. Anne O’Hara.
Future developments 
They include the imminent opening of 12 
designated radiation oncology in-patients beds in 
SJH which will allow the transfer of more complex 
cases such as patients with Head and Neck cancer 
and Upper GI cancer to the St. James’s centre 
for radiotherapy treatment. Although Intensity 
Modulated Radiation Therapy (IMRT) is available 
in SLH, treatment delivery time is lengthy. Rapid 
ARC IMRT which is available in the St. James’s 
centre reduces treatment delivery time which is 
particularly attractive for these complex cases 
as it is more comfortable for the patient but 
also allows an increase in the number of cases 
that can be treated and a further reduction in 
treatment planning time for these patients. 
By early 2014 extracranial stereotactic radiotherapy 
will be available in the St. James’s centre. 
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1.5 Surgical Oncology
The Cancer Programme at SJH has been built 
on a multidisciplinary integrated model, and the 
importance of cancer surgery within this structure 
is presented in this report for each cancer site. 
Currently, approximately 27% of all hospital 
discharges from the hospital are cancer-related. 
The key strengths within surgical oncology at  
the hospital are as follows: 
High-volume hospital and high-volume surgeons 
for oesophageal/gastric, lung, head and neck, 
maxillofacial, colorectal, breast, gynaecological, 
urological, and skin cancers. 
• National Centre for Oesophageal and  
Gastric Cancer.
• National Centre for Early Mucosal Neoplasia  
of the Oesophagus.
• National Maxillofacial Centre.
• Supra-regional Programmes in Lung, 
Gynaecological and Head and Neck Cancer. 
• Surgical site sub-specialisation for all  
cancer types.
• Rapid-access structured clinics for all  
cancer sites.
• Integration with gastroenterologists and 
respiratory physicians in state of the art 
diagnostic facility that was opened in 2005.
• Five-surgeon plastic and reconstructive unit link 
closely with head and neck, breast and  
skin programmes.
• Biobanking of all resected oesophageal,  
lung, colorectal and prostate tissue enables 
molecular research in the Trinity Translational  
Medicine Institute.
• Cancer Clinical Trials aligned with All Ireland 
Cooperative Oncology research Group (ICORG).
• Cognate linkage for major surgery across 
several sites: oesophageal and lung, head 
and neck/maxillofacial with reconstructive, 
oesophageal and lung, gynaecological, 
urological and rectal, urological and cardiac.
• Comprehensive vascular and endovascular 
programme, with significant input into 
some complex cancer operations and the 
management of major vascular emergencies.
• Outstanding cross-sectional radiology for 
cancer staging, including CT/PET and MRI, as 
well as specialist interventional radiology for 
the management of complex cancer cases and 
surgical complications.
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1.6 Palliative Care
Background
Palliative care is an approach that improves the 
quality of life of patients and their families facing 
the problems associated with life threatening 
illness, through the prevention and relief of 
suffering by means of early identification and 
impeccable assessment and treatment of pain  
and other problems; physical, psychosocial  
and spiritual. 
Palliative care:
• Provides relief from pain and other  
distressing symptoms.
• Affirms life and regards dying as a  
normal process.
• Intends neither to hasten or postpone death.
• Integrates the psychological and spiritual 
aspects of patient care.
• Offers a support system to help patients live  
as actively as possible until death.
• Offers a support system to help the family  
cope during the patients illness and in their 
own bereavement.
• Uses a team approach to address the needs 
of patients and their families, including 
bereavement counselling, if indicated.
• Will enhance quality of life and may also 
positively influence the course of illness.
• Is applicable early in the course of illness,  
in conjunction with other therapies that are 
intended to prolong life, such as chemotherapy 
or radiation therapy and includes those 
investigations needed to better understand  
and manage distressing clinical complications.
Palliative care is an essential component of cancer 
care; despite advances in early diagnosis, surgery 
and oncology treatments, many patients with 
cancer will die from their disease.
Early palliative care interventions for patients with 
cancer are associated with many positive benefits 
including better symptom control, better quality 
of life and for some, longer survival. Palliative 
care also assists family and caregivers through this 
experience and works to bring solace to those 
grieving the death of a loved one. 
The palliative care service in SJH was established 
in 1995. It comprises two consultants (23.5 hour 
sessional commitment), a medical registrar, three 
clinical nurse specialists, a medical social worker 
and 0.5WTE of secretarial support. 
The direct administrative supervision and 
governance of the palliative care service is 
conducted through the HOPE directorate.
The strategic policy direction of the service is in 
line with the HSE National Clinical Programme 
for Palliative Care http://www.hse.ie/eng/about/
Who/clinical/natclinprog/palliativecareprogramme 
and is implementing the Programmes’ 
initiatives. These include implementation of 
the national palliative care service referral form 
and the palliative care needs assessment form, 
engagement with the competency framework 
strategy and implementation of national clinical 
guidelines on pain, depression and constipation.
structure
A weekly specialist palliative medicine MDT 
meeting is held where all patients referred to the 
service are discussed and a plan of care agreed. 
Joint palliative medicine and oncology MDT 
meetings are held twice weekly.
A consultation service is provided to hospital 
in-patients. A weekly out-patient clinic is held. 
Patients are also reviewed in the Haematology 
Oncology Day Centre (HODC) on request. 
20
Hospital in-patients with complex specialist 
palliative care needs can be referred for symptom 
control, psychosocial support or end of life 
care. When patients are discharged from SJH 
they can continue to receive specialist palliative 
care through the SJH OPD clinic or through 
community palliative care services based in Our 
Lady’s Hospice and Care Services (OLH&CS) or if 
outside the catchment area, their local palliative 
care service. Some patients are transferred directly 
to OLH&CS for ongoing care as an in-patient. 
The two palliative medicine consultants have joint 
appointments between the two organisations. 
This supports the safe delivery of care as patients 
move frequently between different care settings. 
activity
The demand for the service has been increasing 
year on year. In 2011 the total number of  
in-patient referrals was 927 patients, in 2012;  
1077, and it is projected that by end of 2013  
the total number of referrals will be over 1200. 
The total number of patients referred for  
out-patient consultation is also increasing  
ever year. In 2011 164 patients were referred  
for out-patient consultation, 2012; 173 patients 
were referred and it is projected that by end of 
2013 over 200 patients will be seen in the  
out-patients. The referral rate of cancer patients 
with complex needs will continue to rise due  
to NCCP developments on-site. 
Developments/Innovations
1. The palliative care service is fully integrated 
in the electronic patient referral (EPR) 
system, receiving referrals electronically and 
documenting all patient activity electronically. 
This ensures that the activity of the service 
is captured accurately. This supports regular 
auditing of the service as well as providing 
accurate statistics for the national acute 
hospital minimum data set. The service is  
also linked electronically with OLH&CS 
through the PAS system. This ensures that  
the patient journey from SJH to OLH is 
captured electronically which supports  
the safe delivery of the service.
2. A novel information tool in the form of a 
DVD has been developed as a joint initiative 
between SJH palliative care team and 
OLH&CS, supported by the Regional Cancer 
Programme Office, to inform patients and 
their families of services available to them. 
This innovative tool further supports effective 
care through timely information sharing.
3. Bereavement support is a core component 
of good end of life care and an annual 
bereavement evening is held to support 
bereaved relatives of patients that have died 
while receiving support from the palliative 
care team. This initiative has been evaluated 
positively by attendees, and the aim is to run 
it bi-annually. The format of the evening will 
be used as a template for other services to 
provide bereavement support.
4. The service is actively involved in teaching 
and training of all disciplines both at 
undergraduate and postgraduate levels.  
The Introduction to Palliative Care course 
is run bi-annually in conjunction with the 
Centre for Learning and Development 
(CLD). The service is committed to quality 
improvement through regular audit of 
practice the results of which are shared 
though the HOPE directorate governance 
structures. 
5. To further progress the development of 
a comprehensive specialist palliative care 
service a fulltime SJH palliative medicine 
consultant is required as well as a doubling  
of clinical nurse specialist posts. 
6. The recent appointment of Professor Declan 
Walsh as Professor of Palliative Medicine, 
Faculty of Health Sciences at TCD, School  
of Medicine and Medical Science at UCD  
and OLH&CS will further strengthen the 
research culture of the service.
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1.7 Cancer Clinical Trials Office 
(CCTO)
The CCTO opened in 2003 and Professor John Kennedy was the Director from 2003 until 2009 when 
he was succeeded by Dr. D. O’Donnell. The CCTO has recruited patients in the areas of breast, lung, 
ovarian, oesophageal, mesothelioma, colorectal, melanoma, lymphoma, CML, multiple myeloma, CLL 
and head & neck cancers over the past 10 years. We have conducted clinical trials in all four phases of 
drug development, from phase 1-4 and have been involved in numerous translational studies where 
both blood and tumour samples are collected. 
The recruitment over the 10-year period is variable as it is dependant on what trials and studies 
we have open that particular year. As the years have gone by the trials are not only increasing in 
complexity but the entry criteria are becoming very restrictive. The CCTO works very closely with  
ICORG in sourcing clinical trials and our goal is to provide our patients with access to the newest 
cutting edge therapies.
Figure 1.3  Cancer Clinical Trials 2003-2012
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1.8 Cancer Genetics Service
service
The majority of referrals to the Cancer Genetics 
Programme are accepted within the hospital by 
Electronic Patient Record (EPR). Other referral 
sources include those from General Practioners 
(GP) and are accepted for patients whose family 
members are attending the Cancer Genetic 
Service. (Referrals not accepted are redirected to 
The National Centre of Medical Genetics) Other 
referrals from external consultants are reviewed 
on a case by case basis.
structure
A consultant-led cancer genetics service was 
established in SJH in October 2011.Cancer 
genetics clinics are held every Wednesday 
morning in Breast Care Department.
The Cancer Genetics department is staffed by  
a 0.1 WTE Consultant, a 0.5 WTE CNS,  
1.0 WTE CNM 1 and a 0.5 WTE secretary.
role of the service
SJH has a dedicated specialist cancer genetics 
service which provides risk assessment, 
counselling and genetic testing for individuals  
and families at increased risk of cancer, mainly 
breast and ovarian cancer, however individuals 
and families predisposed to other cancers are 
also seen. The service aims to provide:
• Risk assessment and screening 
recommendations. 
• Counselling and education for patients  
and families.
• Diagnostic genetic testing. 
• Predictive genetic testing. 
• Specific pre and post test counselling. 
• Data collation and tracking. 
• Collaborative participation in relevant basic/
translational/clinical research. 
Patients at risk of harbouring a deleterious 
mutation are counselled regarding the risks 
and benefits of genetic testing. When no 
cancer predisposition syndrome is identified 
for genetic testing screening advice is given 
based on the diagnoses in the family. In all case 
where a mutation has been identified genetic 
counselling/predictive testing is offered to at risk 
family members and a structured surveillance 
programme is established for female mutation 
and this is co-ordinated through the Breast Care 
services and Gynaecology services in SJH.
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Clinical and Translational 
research 
In addition to providing a clinical service we 
are actively involved in clinical and translational 
research. We regularly accrue patients to the 
SJHbio bank and have developed internal and 
external research collaborations. In 2012, original 
research from this department was presented at 
the American Society of Clinical Oncology (ASCO) 
Gastrointestinal Symposium in Florida, the ASCO 
Annual Meeting in Chicago and the European 
Society of Medical Oncology Annual Meeting  
in Vienna.
The IMPACT study was also opened in 2012 at 
SJH. This multi-institutional collaboration led by 
Professor Eeles at the Royal Marsden Hospital, 
London investigating the benefit of prostate 
cancer screening in men genetically predisposed 
to the disease.
Developments in Cancer Genetics 
in 2012
• Complete service revision.
• Patient pathway remodelled.
• Administrative processes introduced.
• Staff roles & responsibilities revised. 
• Nursing competencies established and second 
nurse trained to review patients.
• Introduced new ‘Predictive’ clinics.
• 16 extra consultant clinics held (NCCP funded).
Cancer Genetics service Goals  
for 2013
• Service development via NCCP.
• Introduce G2 speech recognition technology. 
• Exploration of specific database options.
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1.9 Psycho-Oncology
The Psycho-Oncology Service at SJH was formerly 
launched by the Minister for Health in 2005. 
It was the first integrated psycho-oncology 
service nationally and developed the first CNS 
post for mental health nursing in a general 
hospital setting.  Developed from the existing 
Psychological Medicine Service, it promotes the 
same ideals of integrated, multi-disciplinary 
psychological care across all levels of distress 
– mild/moderate and severe and provides 
emergency and elective assessment as well as  
on-going complex psychological care when 
needed. The core service includes Principal  
Clinical Psychologist; Dr Sonya Collier, CNS;  
Mr. Eugene Beirne; Administrator; Ms. Karen 
Shine, and Consultant Psychiatrist;  
Dr Anne-Marie O’ Dwyer. 
In addition to providing clinical care, the team 
also provides training, supervision and education 
for health workers; has presented at national 
and international conferences on the topic of 
psycho-oncology and has published in a number 
of peer reviewed journals.  A recent innovation by 
the service was the development of an award-
winning cancer-related fatigue manual and DVD. 
The service has been the recipient of a number 
of awards including the 2005 – HSE innovation 
in Healthcare Awards (First prize in Hospital 
Category); 2012 Irish Healthcare Awards: First 
prize in Hospital Category and An Duais Mhor, 
best project in all categories and was a finalist in 
the 2013 Healthcare Innovations Awards. 
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1.10 Allied Health Services
The SCOPe Management Unit comprises of 
Speech and Language Therapy, Medical Social 
Work, Clinical Nutrition, Occupational Therapy 
and Physiotherapy. SCOPe staff members work  
as an integral part of the cancer MDT at SJH.  
We aim to provide the highest quality, evidence 
based care to all cancer patients. SCOPe has 
secured funding for research and has pioneered 
many cancer studies and audits over the last 
number of years. 
Clinical Nutrition
Clinical nutrition activity has increased substantially 
over the last 10 years, most noticeably in the 
specialities of upper and lower gastrointestinal 
cancer surgery, head and neck cancer surgery, 
gynaecological oncology surgery and  
medical oncology.
There has been some increase in staffing to help 
meet the significant growth in activity. However, 
demand on services continues to grow, reflecting 
SJH’s designation as a cancer centre, increasing 
patient complexity and the need for intensive 
clinical nutrition input throughout the patient’s 
cancer journey. The department is fortunate to 
have two clinical specialists working in the areas 
of upper gastrointestinal cancer surgery and 
radiation oncology.
There has been a significant increase in the 
number of cancer patients managed on both 
home enteral and parenteral nutrition support, 
which helps to facilitate early discharge from 
hospital. We have observed a 30% increase 
in home enteral feed discharges in upper 
gastrointestinal cancer surgery between 2008  
and 2012 due to improved post-operative 
nutrition support practices. The number of 
medical oncology patients discharged on home 
parenteral nutrition or home intravenous fluids 
has increased by 100%; over forty patients 
have successfully been discharged home who 
previously would have had to remain in hospital. 
These interventions make significant contributions 
to the quality of life of patients receiving 
treatment for cancer in SJH.
Clinical nutrition staff have developed and 
reviewed resource information on nutrition for 
cancer patients for use nationally and contributed 
to the cancer-related fatigue self-help resource for 
patients developed by Psycho-Oncology services 
in SJH. Clinical nutrition staff have presented 
widely on nutrition and cancer including 
presentations at Grand Rounds, Irish Nutrition 
and Dietetic Institute study days, on the Royal 
College of Surgeons in Ireland (RCSI) Specialist 
Registrar education programme and at multiple 
Irish Cancer Society (ICS) meetings.
Figure 1.4  Clinical nutrition activity in upper Gi Cancer Surgery 
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audit and research
The department of clinical nutrition, working in 
collaboration with Professor John Reynolds, has 
secured almost €1,000,000 in cancer research 
funding over the last 10 years, with Dr. Aoife 
Ryan and Dr. Laura Healy both successfully 
completing PhDs. The aim of these studies was to 
gain a better understanding of different cancers 
(oesophago-gastric, breast and colorectal), and 
improve patient outcomes and nutritional status 
throughout treatment for upper gastrointestinal 
cancer. This work has resulted in 15 peer 
reviewed publications and numerous international 
and national conference presentations and 
associated conference publications, including  
the first Irish studies linking obesity and  
metabolic syndrome to cancer.  
Future Developments
At the end of 2012, a study to examine 
the incidence, presentation, diagnosis and 
management of malabsorption after surgical 
resection for cancer of the stomach/oesophagus, 
and its impact on nutritional status and 
micronutrient levels was initiated.
An enhanced recovery after surgery (ERAS) 
programme of multidisciplinary peri-operative 
care, designed to “minimise post-operative organ 
dysfunction and return the patient to normality” 
as soon as possible, is being implemented in the 
area of colorectal cancer surgery.
Medical Social Work
Social workers focus on the psychosocial aspects 
of patient care, incorporating both emotional and 
practical support to patients and their families. 
They provide comprehensive assessment of 
patients’ psychological and social needs as well 
as assessing any risks to the patient. They provide 
counselling for patients and families, practical 
advice and information and advocacy and liaison 
work with community services to facilitate 
effective discharge planning and aftercare.
Over the past ten years the social workers have 
provided a service to an increasing number of 
patients with cancer in departments other than 
oncology and haematology particularly head and 
neck cancer, gynaecology and general surgery. 
Demographic and socio-economic changes 
nationally, have been reflected in the increased 
complexity of patients’ circumstances. As a 
result, many patients have been assisted by social 
workers including those from different ethnic 
backgrounds, those with limited family support, 
families who have been financially devastated by 
the recession and older patients who are living in 
extreme isolation.
Developments/Innovations
The social work team have played a leading  
role in the IASW (Irish Association of Social 
Workers) Haematology, Oncology Social Work 
Group, establishing a website in 2012  
(www.socialworkandcancer.com) which  
provides information and advice for patients  
and their families.
The “Care to Drive” scheme has been successfully 
established in collaboration with the ICS for SJH 
patients who are receiving treatment for cancer.
The social work service in SLROC at SJH was 
established last year.
Occupational Therapy (OT)
Occupational therapy plays an essential role at 
all stages of the cancer care pathway. The OT 
works as a key member of the MDT to enable 
patients achieve their optimum level of functional 
independence and quality of life.
In January 2005, a 0.5 WTE senior OT was funded 
to provide a dedicated service to oncology and 
haematology day cases and out-patients.  
A senior OT covers all oncology and haematology 
in-patients and out-patients, based on need.
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activity
Since the commencement of this post, the OT 
service has observed a 613% increase in OT 
time to medical oncology activity and a 75% 
increase in time to haematology when comparing 
statistical activity data between 2005 and 2012. 
The OT delivers approximately 900 individual 
patient contacts to oncology and haematology 
in-patients per annum.
Developments/Innovations
Staff grade rotations were commenced to 
address increasing clinical demand as well as 
developing a specialist oncology and haematology 
skill-set amongst staff grade therapists. The 
OT department has implemented core clinical 
competencies to support this rotation.
The OT has developed comprehensive 
haematology and oncology resource folders 
which have been shown to significantly improve 
knowledge and expertise amongst therapy staff.
The OT was principally involved with medical and 
nursing colleagues in prioritising minor capital 
expenditure following a donation from the 
Bone Marrow & Leukaemia Trust. These funds 
were utilised to purchase high level posture 
and pressure care equipment for in-patients on 
Denis Burkitt ward. This equipment has been 
instrumental in facilitating patients to sit out 
of bed in a more time efficient manner and 
improving quality of life.
The OT is actively involved in the Association of 
Occupational Therapists in Ireland Palliative Care 
and Oncology Advisory Group. 
The OT can provide essential enabling equipment 
in order to facilitate discharge home. This has 
resulted in decreasing length of stay, facilitating 
safe discharge home and improving quality of life. 
A joint physiotherapy and OT pilot lung cancer 
breathlessness clinic was run which demonstrated 
significant improvements.
Future developments
The department is committed to ongoing 
audit and development of the oncology and 
haematology OT service. Further development 
of patient education and self-management 
strategies are planned.
Physiotherapy
Physiotherapy is essential in the care of a patient 
with cancer. Trends in cancer incidence and 
survivorship, along with an aging population, 
are drivers for the current increasing need for 
physiotherapy and this will continue for decades 
to come. With one in three women and one in 
two men developing cancer in their lifetime,  
most physiotherapists, regardless of area of 
specialty, will treat patients who have been 
touched by cancer. 
Physiotherapy has a key role to play in the 
management of patients throughout their cancer 
journey. The primary goal is to assist the person 
with cancer in achieving maximum physical 
functioning within the limits imposed by their 
disease and/or treatment.
Yet physiotherapy is still not a priority 
consideration in cancer treatment. Many hospitals 
offer a one-time post-operative physiotherapy 
visit only consisting of respiratory care, range 
of motion and teaching the patient about 
lymphoedema. However, as with most surgeries, 
people post-cancer surgery are likely to exhibit 
musculoskeletal symptoms for weeks or months 
after surgery. 
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Here at SJH we believe that physiotherapy is required not only in the post-surgical phase and therefore 
see patients pre-operatively if possible. We have found that pre-operative management to optimise 
patients e.g. inspiratory muscle training and pre-rehabilitation in patients with lung cancer, improves 
patient outcomes. Additionally if we know that a patient will begin chemotherapy and/or radiation 
after surgery, we believe it is our job to address the impending cardiopulmonary and functional issues. 
With this in mind the physiotherapy department at SJH worked closely with the ARC unit on the South 
Circular Road in 2011 and provided a general exercise programme to attendees.
As teamwork is a key standard in cancer care, the physiotherapists meet regularly with the other 
members of the multidisciplinary teams and have collaborated with the breast care nurses in 
development of the breast care booklet for patients.
Figure 1.5 represents the breakdown of physiotherapy treatments received by patients attending  
SJH in all cancer specialties. The figure compares 2002 and 2012. 
In general, for the national or superregional cancers for which SJH is the centre of excellence there  
has been a steady increase in the number of treatments given over the 10 year period 2002 – 2012 
(see fig 1.6).
Figure 1.5 Comparative Breakdown of physiotherapy treatments 2002 vs. 2012
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Future Developments
In keeping with evidence-based practice, we will 
develop our role in the area of exercise, cancer 
and survivorship. An exercise booklet and an 
individualised exercise programme have been 
devised by the physiotherapy department for 
haematology patients. This will be rolled out and 
audited in the national bone marrow transplant 
unit. A formal study to examine physical fitness 
and physical activity levels in a group of patients 
following haematopoietic stem cell transplant will 
be completed in the next year.
As exercise can prevent recurrence and increase 
survival we will be looking at developing specific 
studies and exercise programmes with our Trinity 
College Dublin (TCD) discipline of physiotherapy 
to explore this topic further.
Speech and Language 
Therapy (SLT)
Speech and Language therapists play a crucial 
role within the cancer care MDT, from the pre 
intervention assessment period, through the pre 
and post surgery, chemo/radiotherapy phases, 
subsequent in and out-patient rehabilitation and 
palliative care in the areas of:
• Head & Neck Oncology.
• Oesophageal Oncology.
• Lung Oncology.
• Medical Oncology & Haematology.
Therapists work with patients presenting with 
communication and/or swallow impairment,  
also providing psychosocial support and 
information to patients and carers, including 
arranging pre-operative visitors who have 
undergone similar surgery.
We have the largest SLT head and neck cancer 
service in Ireland with two senior therapists.  
These provide in and out-patient assessment 
(including objective assessment with 
videofluoroscopy & fiberoptic endoscopic 
examination of swallowing (FEES)) and treatment 
of the increasingly complex patient profile 
presenting over the past decade. 
Figure 1.6 physiotherapy Treatments 2002 vs. 2012
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SLT attendance at joint head and neck clinics has 
expanded to reflect the growth in referrals from 
this service. This facilitates increased ongoing 
liaison with community/primary care services for 
this patient group.
We have over 70 out-patient laryngectomies on 
our caseload to whom we provide long term 
follow up and maintenance of their alternative 
communication modalities (Surgical Voice 
Restoration and Electrolarynx) as well as running 
support groups. 
We have retained our specialist therapists 
allowing us to continue to provide the necessary 
specialist standard of care required for this patient 
group. This has resulted in our department having 
the expertise to run the Macmillan Surgical Voice 
Restoration Course for SLTs, with 57 therapists 
trained to date nationally.
activity 
Head and neck Cancer: Over the last 10 years 
there has been significant growth in referrals to 
the head and neck oncology service: In-patient 
referrals have grown by 30% and out-patient 
referrals by 70%. Clinical time spent with this 
patient group has increased by 73% for in-
patients and by 200% for out-patients reflecting 
the growing demand for service and also the 
increasing complexity of this caseload.
oesophageal Cancer: Referrals from upper GI 
oncology have doubled in the last 5 years, and 
clinical time has increased by 48%. 
Medical oncology/Haematology: There has 
been a steady demand for SLT services to this 
patient group with between 60-85 in-patient 
referrals annually for the past 5 years. 
lung Cancer: There has been significant growth 
in the demand for SLT service post thoracic 
surgery. These patients are often complex 
tracheostomy cases requiring significant time 
input regarding communication and swallow.
Developments/Innovations
• Development of a FEES assessment clinic for 
cancer patients. 
• Development of a pureed diet for oral cancer 
patients, allowing for earlier transition onto  
oral feeding.
• Development of treatment programs for trismus 
(difficulty in mouth opening) including provision 
of Therabite devices, thereby improving quality 
of life associated with swallowing, oral care and 
speech functions.
• Development of a basic grade staff rotation 
into head and neck and oesophageal cancer 
speciality areas.
• Development of new expertise in communication 
and swallowing deficits related to combined 
treatment modalities for patients with the 
advent of chemoradiotherapy.
• Appointment of an additional senior SLT post 
for head and neck cancer in 2006, following 
the appointment of a Consultant Maxillofacial 
Surgeon in oncology.
• Appointment of a clinical specialist SLT in 
radiation oncology in 2012.
• Education at undergraduate and postgraduate 
level in TCD, University of Limerick and Dublin 
Dental School & Hospital.
Future developments
• Support for and development of our new 
clinical specialist post for radiation oncology. 
• Linking the head and neck surgery and 
radiation services to provide a more seamless 
coordinated service for patients.
• Further development of our FEES assessment 
clinic for cancer patients, with training for 
speech and language therapists to complete 
this assessment independently.
• Development of our service to medical 
oncology/haematology/lung cancer patients.
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1.11 Diagnostic Radiology
Diagnostic and interventional radiology is 
provided by the radiology department. This 
comprises of 13 consultants, 65 radiographers, 
8 nurses and 12 specialist registrars. The 
department performs approximately 180,000 
examinations per annum and a significant 
amount of the complex departmental activity 
relates to oncology. The department provides all 
imaging modalities and has expanded greatly 
since 2006. In that time period the department 
has started a PET/CT service, increased the 
number of clinical MRI units from one to three, 
opened a research facility with a high strength 
MRI, opened two SPECT/CT units and a new 
interventional room. There have also been 6 
new consultant radiologist appointments. The 
department provides both an urgent and routine 
oncology imaging service and all turn around 
times are within HSE and NCCP guidelines. 
The department provides full support to all 
cancer MDTs, which now represent a substantial 
workload. The centralisation by the NCCP of 
oncology care has lead to a significant increase 
in workload for the radiology department. This is 
readily illustrated by the mammographic activity 
change since 2006 (fig 1.9).
The clinical department at SJH has very well 
developed academic structures with established 
links to TCD and the faculty of radiology. TCD  
has funded a research fellow who is assisting  
with oncology research projects. In 2008 the 
Centre for Advanced Medical Imaging was 
opened. This comprises of a high strength  
3T MRI scanner and is the only unit of its type  
in the country. Among its ongoing research 
projects are both translational and clinical 
oncology imaging studies.
SJH introduced a Picture Archiving and 
Communication System (PACS) in the second 
half of 2006. This has quickly become integral to 
oncology patient care. In the next few years the 
department will integrate this with the national 
PACS network (NIMIS). The NIMIS project was led 
by staff from SJH radiology and medical physics, 
notably Professor Neil O’Hare from MPBE.  
As more hospitals are integrated this will prove  
of extreme importance in oncology care  
and research.
In 2009 the national PET/CT unit was opened in 
SJH. This has become the busiest PET/CT unit in 
the country performing up to 14 examinations 
per day. Approximately 40% of these patients are 
referred from outside the SJH cancer network. 
We plan to develop the service over the next few 
years by introducing new radiopharmaceuticals 
and further integrating PET/CT into radiation 
oncology planning.
Consultant staff
diagnostic radiology
• Dr. Peter Beddy
• Professor Mary Keogan
• Professor James Meaney
• Dr. Graham Wilson
interventional radiology
• Dr. Niall McEniff
• Dr. Michael Guiney
• Dr. Mark Ryan
peT/CT and nuclear medicine
• Dr. Grainne Govender
• Dr. Ciaran Johnston
• Dr. Niall Sheehy
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Breast imaging
• Dr. Susannah Harte
• Dr. Sylvia O’Keeffe
• Dr. Ronan McDermott
activity
Complex imaging activity has almost doubled 
since 2006 (fig 1.7). Figure 1.8 demonstrates 
the range of activity and figure 1.9 shows the 
units that have undergone the most significant 
changes. The increase in activity in breast imaging 
is notable and is a result of the streamlining of 
breast care by the NCCP and a demonstration of 
the increased radiology workload that comes with 
centralisation of oncology care.
Figure 1.7 Complex diagnostic imaging activity by patient number since 2006 
[incorporates peT/CT, CT, mri, uS, nm, mammography and 
interventional radiology]
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Figure 1.8 Complex imaging by modality since 2006
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1.12 Histopathology
The Department of Histopathology and Cytology 
plays an integral role in cancer services in SJH. 
Diagnostic services are provided to SJH, GPs in the 
Greater Dublin area, the Dublin Dental Hospital 
(DDH) and some external hospitals.
The department provides an opinion on all 
tumour biopsy material as well as diagnosis, 
grading and staging of tumour resections done 
within SJH. 
The department also provides second opinions  
on the pathology of all patients referred from 
outside hospitals to SJH as well as consultation 
second opinions to hospitals around the country 
and the UK. 
The diagnostic cytopathology service is provided 
by two specialised cytopathologists who report 
fine needle aspiration (FNA) and exfoliative 
cytology that is integral to the diagnosis, staging 
and management of cancers of the lung, breast, 
hepatobiliary system and pancreas, head and 
neck including thyroid and the haematolymphoid 
system. Rapid on site evaluation of cytologic 
diagnostic samples is also available on request. 
In addition, a weekly clinic is provided by the 
cytopathologists who are expert in performance 
and interpretation of FNA samples. Hospital  
in-patients, out-patients and GP patients have  
access to this clinic. 
There are 11 weekly MDT meetings and two 
fortnightly meetings where the pathology, 
radiology and clinical features of cases are 
discussed so that appropriate treatment plans  
can be devised for patients. 
structure
Subspecialty reporting of cases is a feature 
unique to SJH. The workload is divided into 
dermatopathology, gynaecological pathology, 
pulmonary pathology, breast pathology, 
gastrointestinal pathology, urological 
pathology, head and neck/dental pathology, 
haematopathology, liver pathology and molecular 
pathology with each pathologist reporting within 
two or three specialities only. 
We work with the Cancer Molecular Diagnostic 
(CMD) laboratory which is the only accredited 
molecular diagnostic laboratory in Ireland. To 
date CMD has provided a de facto National 
molecular diagnostic service, primarily for 
haematological malignancies. More recently 
solid tumour molecular diagnostics have become 
critical to the appropriate management of 
patients with common cancers such as breast, 
colon, lung and malignant melanoma and these 
requirements will increase hugely over the next 
number of years. EGFR, KRAS and BRAF testing is 
performed to satisfy the prescribing requirements 
of Gefitinib/Erlotinib, Cetuximab/Panitumab and 
Vemurafinib respectively. 
A strong strategic alliance has been forged 
between Histopathology and CMD and the SPD 
Translational Laboratory in TCD to develop and 
validate clinically relevant biomarkers with the 
support of industrial and academic collaborators. 
The laboratory is a European reference laboratory 
for cancer molecular diagnostics clinical trials. It is 
partnered with the European Thoracic Oncology 
Platform which was founded in 2009 with a 
focus on promoting collaboration in clinical 
and translations research in lung cancer and 
mesothelioma in Europe.
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Developments/Innovations
The department has been chosen as a centre 
involved in the recently started colon cancer 
screening programme. 
SJH is the only hospital in Ireland providing a 
Mohs surgery service to skin cancer patients.  
A second surgeon has started and the laboratory 
is involved in sample processing as well as quality 
control and support. 
Molecular pathology will become increasing 
important in the treatment of cancer. Laboratory 
testing will be required to assess the specific 
vulnerabilities of tumours so that patients can be 
selected for specific treatments. The department 
is already involved in molecular analysis for some 
tumours and expects to expand this service. 
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1.13 Cancer Research
Translational medicine is the key research strength 
of the SJH and TCD programme. This is greatly 
enabled by the real proximity of the hospital to 
the research laboratories. Internationally, the 
move to formalise the translational process has 
led to the strategic formation of specialised 
Institutes of Translational Medicine. The School 
of Medicine of Trinity College has established the 
Trinity Translational Medicine Institute (TTMI) in 
the Trinity Centre on the campus of SJH. TTMI 
is formed from the merger of the Institute of 
Molecular Medicine (IMM) and Sir Patrick Dun 
(SPD) with over 40 Principal Investigators (PI) and 
150 scientists. 
The mission of the TTMI is to synergise 
translational research and to develop an 
international standard research facility on the 
TCD SJH campus with access to the breadth of 
patients within Trinity Health Ireland (THI). TTMI 
will contain the spectrum of translational medical 
research disciplines from bench sciences to 
patient-focused research, creating a new model 
of Trinity Translational Research (fig 1.10).  
TTMI will also train the next generation  
of clinicians and basic researchers in  
translational medicine. 
The School of Medicine has, in recent years, 
significantly increased grant funding for 
biomedical research from Exchequer and  
non-Exchequer bodies, such as industry and 
charities, with particular success from EU 
schemes. In 2011-12 the School of Medicine  
was awarded 22.5% of all research grants 
in TCD. Furthermore, School of Medicine 
investigators have an outstanding record in  
the delivery of world-class medical research 
reflected in high impact publications in the 
leading international journals. Expertise in 
translational research in these key areas spans  
the entire spectrum from cellular based 
approaches, in vivo animal models to patient-
orientated research. Furthermore, the links and 
proximity with the newly opened Wellcome Trust/
Health Research Board facility will give TTMI a 
unique position to engage in research as part  
of clinical trials. 
The Institute will be a central component of 
‘Trinity Health Ireland’, an initiative combining the 
strengths of the College’s School of Medicine and 
its affiliated teaching hospitals and community 
services. TTMI will combine the excellence of 
these core institutes across TCD and SJH, and 
Trinity Health Ireland (see fig 1.11). 
Figure 1.10 model of Trinity Translational research
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Figure 1.11 Trinity Translational 
medicine institute (TTmi)
The TTMI Translational Cancer focus will cover a 
wide spectrum of disease sites and examine key 
drivers of oncogenesis. The research conducted 
spans oncology and includes all cancer sites, 
but with a major focus on lung, oesophageal, 
thyroid, colorectal, gynaecological, breast, skin, 
and haematological malignancies. Themes 
include the following: cancer stem cell biology; 
the metastatic cascade; the inflammasome; 
resistance mechanisms to chemotherapy and 
radiation therapy; radiation biology; obesity as a 
driver of inflammation and cancer; mitochondrial 
function and cellular energetics; next generation 
diagnostics in cancer; nanotechnology; disease 
modelling in cancer; health economics and 
health services research. Each programme is 
underpinned by bioresources and many are linked 
to clinical trials. 
TTMI cancer investigators have already been 
hugely successful in securing Irish and EU funding 
from Science Foundation Ireland (SFI), Health 
Research Board (HRB), ICS, The Wellcome Trust, 
EU 7th FP and grant income over the past 5 years 
and totals in excess of 60 million euros. This is 
coupled with significant industrial support from 
Pfizer, Merck Serono, Lilly Oncology, Abbott, 
Johnson & Johnson, Roche-Genentech, Randox 
Laboratories, Clovis and Glaxo-Smith Kline. In 
addition, several investigators have established 
their own or work with charitable foundations 
to raise much needed research income for TCD 
[e.g. C.R.O.S.S. and Emer Casey Foundation 
etc.], along with gaining philanthropic donations. 
Indeed, the Durkan Leukaemia Research 
Laboratories in IMM were built with  
philanthropic monies.
Postgraduate education
TTMI will create a unique translational  
biomedical research environment for post-
graduates. A number of postgraduate courses 
that are highly successful are already running 
from TTMI. These include the MSc Molecular 
Medicine (approximately 25 students per year) 
that is running for 8 years. Although a more 
recent course, the MSc Intercalated Masters has 
growing public popularity. In 2012, a new MSc in 
Translational Oncology was launched with  
the first year intake of 20 students which was  
a great success. Previously IMM was successful  
in obtaining a HRB PhD training programme  
and a MMI Clinician Scientist PhD Training 
Scheme. In 2011-15 TTMI houses a MMI PhD 
training programme. 
A long-term objective is for TTMI to develop 
future PhD training for basic scientists and PhD/
MD training courses for clinician scientists. In 
particular, due to the proximity of the DCCR the 
potential to develop schemes with the Wellcome 
Trust will be explored. 
Current Postgraduate Courses
• MSc Molecular Medicine 
• MSc Translational Oncology 
• MSc Intercalated Masters
• MMI Scholars PhD
TCBE TCINCRANN
TBSI
TRINITY TRANSLATIONAL MEDICINE INSTITUTE
TRINITY COLLEGE DUBLIN
DCCR MISACAMI

2section 2: Site Specific  Cancer Audit

41
2.1 Lung Cancer
structure
rapid access lung Centre
SJH is one of the eight nationwide rapid access 
centres specialising in lung cancer. The centre 
provides rapid access diagnostic and staging 
to patients within a 4-6 week time frame. All 
bronchoscopies are provided on a next list basis 
which means there is no waiting list for any 
patient needing this service. The service aims to 
be in a position to determine appropriate primary 
therapy within 4-6 week time frame. Where CT 
and Bronchoscopy are the only investigations 
required this is usually achieved within 2 weeks. 
Where additional investigations such as CT 
guided biopsy, US guided biopsy, EBUS, PET, 
MRI or mediastinoscopy are required, the aim is 
within 6 weeks of initial contact. The respiratory 
consultants in SJH specialise in providing 
bronchoscopy under fluoroscopy and EBUS 
guided TBNA for mediastinal staging.  
The Rapid Access Lung Centre continues  
to reach and exceed targets in 2013.
Rapid Access lung figures have been submitted 
to the NCCP since mid 2010. 46% of all patients 
diagnosed in SJH in 2012 came via RAL clinic.
multidisciplinary Team (mdT)
We implement a long established weekly 
multidisciplinary team meeting, with MDT 
approach to management of all patients. This 
includes regular tele-link with tertiary hospitals in 
Mullingar, Tullamore, Letterkenny, Limerick and 
Waterford. The MDT is organised by a full time 
MDT coordinator. There is also a MDT planning 
meeting which takes place at the end of every 
week to ensure patients waiting for difficult or 
complex biopsies are discussed with radiology 
consultants post bronchoscopy lists and the 
patients who are having surveillance scans as 
part of the follow up care are discussed in a 
multidisciplinary environment.
radiology
The radiology department has an essential role in 
the work up and treatment of patients with lung 
cancer in SJH. Initial CT staging is complemented 
by PET/CT. There are four thoracic radiologists 
who help present the lung cancer MDT and they 
also perform over 200 percutaneous CT guided 
lung biopsies per year for tissue diagnosis. The 
Centre for Advanced Medical Imaging (CAMI), 
based in the radiology department, is developing 
new imaging techniques to image lung cancer, 
including diffusion and perfusion MRI.
Cardiothoracic Surgery
Our cardiothoracic surgical unit at SJH opened 
in 2000. It has two cardiothoracic surgeons and 
an experienced dedicated MDT delivering expert 
surgical care to patients throughout Ireland. 
Thoracic surgeons in SJH accept referrals from 
supra-regional hospitals including AMNCH, 
Beaumont hospital and tertiary hospitals which link 
in through our weekly MDT meetings. The lung 
cancer surgical service in SJH is unique in Ireland 
both in terms of volume and complexity.
The surgeons have a special interest and 
experience in extended resections for the 
treatment of locally invasive lung cancers.
On average, over the last ten years 35% of 
patients each year are treated with curative lung 
surgery which is a rise of 10% since 2003.  
The cardio thoracic team carries out over 45%  
of curative lung cancer resections in Ireland.
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radiation oncology
The radiation oncology department provides a 
referral and review service for SJH patients who 
may require radiotherapy treatment. There is also 
a specialist liaison nurse based in SJH. 
medical oncology
SJH have a dedicated medical oncologist for lung 
cancer, Dr Sinead Cuffe. We provide in-patient 
and out-patient chemotherapy, non-surgical 
treatment of cancer and supportive and palliative 
care. A patient may also be eligible to take part in 
a clinical trial of a new cancer treatment, and SJH 
have an active lung cancer clinical trials service. 
radiofrequency and microwave  
ablation treatment 
Radiofrequency and Microwave Ablation 
(RF&MA) treatment is a relatively new minimally 
invasive technique for treating lung cancer. Both 
techniques involve percutaneous placement of 
a heat probe into a tumour under CT guidance. 
RF&MA are ideally suited to patients who are 
medically unfit for surgery. They are well tolerated 
by most patients and have equivalent response 
rates when compared to stereotactic radiotherapy. 
They are suitable for the treatment of primary 
and secondary lung tumours under 3 cm and 
have been performed in SJH by Dr. P. Beddy and 
Dr. M. Guiney for the past year. RFA treatment 
is a speciality only performed in SJH under our 
specialist pulmonary radiology consultant.
lung Cancer Trends
Lung cancer is the leading cause of cancer related 
death in Ireland; the incidence of lung cancer 
has been rising. The rate has increased more 
rapidly in women and from 2003 to 2012 the 
rate of increase is 61% in SJH female patients. 
The increase in men since during 2003 to 2012 
is 53% in SJH. In 2011 lung cancer became the 
leading cause of cancer related death among 
women in Ireland, overtaking breast cancer.
The following is a report on 4,256 newly 
diagnosed and/or treated lung cancers in SJH. 
There has been a 127% increase in lung cancer 
diagnoses in the last ten years making this by far  
the largest cancer service in SJH.
Figure 2.1 lung Cancers 2003-2012
While smoking is the most common risk factor 
associated with lung cancer, a significant 
percentage occurs in never-smokers. Radon, 
second-hand smoking, occupational exposure, 
indoor air pollution and genetic predisposition are 
risk factors for the development of lung cancer in 
non-smokers. Lung cancer not related to smoking 
has different clinical, pathological and molecular 
findings. It is commonly adenocarcinoma. It occurs 
more frequently in women, particularly women 
of Asian ancestry. It tends to occur at a younger 
age and has a better prognosis than lung cancer 
in smokers. Mutations in EGFR and EML4-ALK 
occur more commonly in never-smokers or light 
smokers enabling targeted therapy with tyrosine 
kinase inhibitors and crizotinib respectively.
Table 2.1 Smoking incidence SJH patients
Female Male
Never Smoker 137 (7%) 107 (4%)
Ex- Smoker 724 (40%) 1,109 (45%)
Current Smoker 832 (46%) 1,074 (44%)
Unknown 97 (5%) 157 (6%)
Lives with Smoker 13 (2%) 6 (1%)
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On average one third of all lung cancer patients are treated with curative resection.
 
 
Figure 2.2 lung cancer surgery 2003-2012
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Surgery 70 68 110 97 129 124 174 162 193 208
% of patients who had surgery  25% 22% 34% 30% 32% 31% 40% 33% 34% 33%
Table 2.2 Comparison of national versus SJH workload
Caseload of sJH in comparison to national Figures 2007 2008 2009 2010 2011
Total new lung cancer cases nationally 1,976 2,069 2,061 2,255 2,172
Total new lung cancer case SJH 415 394 446 512 587
% of national workload (21%) (19%) (22%) (23%) (27%)
Total who had surgery nationally 311 345 381 391 400
% of national patients who had surgery (16%) (17%) (18%) (17%) (18%)
Total who had surgery in SJH 129 124 174 162 193
% of patients in SJH who had surgery (41%) (36%) (46%) (41%) (48%)
The average age of diagnosis is 66, median age is 68 and in comparison to UK where the average 
age is 71 and median age is 72. The average age at diagnosis across the 10 year period has remained 
comparable year-on-year. 
Table 2.3 age at Diagnosis 2003-2012
2003-2012 Female Male
0-20 2 3
21-30 9 11
31-40 19 18
41-50 100 117
51-60 347 454
61-70 615 868
71-80 550 763
81-90 158 217
91-100 3 2
7% of patients are under the age of 50 at time of diagnosis. Within this group 8% of females and 6% 
of males diagnosed with lung cancer are under 50 years of age. This figure dramatically increases to 
87% for females and 85% for males diagnosed in the 50-70 age group.
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Clinical and Pathological staging
Table 2.4 Clinical Staging 
Clinical stagea 
2003-2009
6th edition
2010-2012
7th edition
Stage IA 303 363
Stage IB 394 164
Stage IIA 12 124
Stage IIB 134 124
Stage IIIA 195 244
Stage IIIB 321 107
Stage IV 427 360
Unknown 292 72
a)  Please note the above table excludes mesothelioma patients and 
small cell lung cancer patients
Table 2.5 Clinical Staging - Small Cell 
lung Cancer
small Cell lung Cancer 2003-2012
Limited Stage Disease 214
Extensive Stage Disease 288
Unknown 42
Table 2.6 pathological Staging
Pathological 
stage
6th edition
2003-2009
7th edition
2010-2012
Stage 0 0 5
Stage IA 183 197
Stage IB 192 94
Stage IIA 32 97
Stage IIB 128 46
Stage IIIA 143 114
Stage IIIB 52 2
Stage IV 16 8
Table 2.7 pathological Staging for 
Small Cell lung Cancer
Pathological 
stage
6th edition
2003-2009
7th edition
2010-2012
0 0 1
IA 2 4
IB 2 0
IIA 3 0
IIB 2 0
IIIA 0 0
IIIB 0 0
IV 0 0
Table 2.8 Tumour morphology  
2003-2012
Morphology occurrences Percent
Adenocarcinoma 1,553 36
Squamous 1,463 34
SCLC 547 13
NSCLC 305 7
Mesothelioma 122 3
Typical Carcinoid 103 2
Not Histologically Proven 51 1
Pleomorphic 29 0.7
Large Cell 25 0.6
Mixed Cell 23 0.5
Atypical Carcinoid 23 0.5
Adenosquamous 21 0.5
Large Cell Neuroendocrine 14 0.3
Br/Alve 12 0.3
Other 9 0.2
Baseloid 3 0.1
Undifferenciated 3 0.1
Neuroendocrine 2 0
Spindle Cell 1 0
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Table 2.9 position of Tumour  
2003-2012
Position occurrences Percent
RUL 1207 28
LUL 1090 25
RLL 644 15
LLL 553 13
RML 206 5
Bronchus 114 3
Right Lung 98 2
Pleural Effusion 95 2
Left Lung 89 2
Pleura 75 2
Mediastinum 73 2
Both Lungs 15 0.3
Lymph Nodes 12 0.3
Unknown 31 0.7
Table 2.10 Treatment given to patients 
2003-2012
Treatment Given  
2003-2012
occurrences Percent
Surgery 1,388 33
Best Supportive Care 802 19
Oncologist Referral 762 18
Surgical Procedure 581 14
Chemotherapy 581 14
Palliative Radiotherapy 423 10
Chemo/Radiotherapy 337 8
Adjuvant Chemotherapy 286 7
Radiation Oncology referral 274 6
Palliative Chemotherapy 238 6
Radiotherapy 175 4
Radical Radiotherapy 111 3
Adjuvant Radiotherapy 94 2
Neo Adjuvant Chemotherapy 85 2
Surgical Referral 51 1
No Active Cancer Treatment 47 1
Neo Adjuvant Radiotherapy 15 0.4
Radio Frequency Ablation 5 0.1
No Treatment given at present 4 0.1
Brachytherapy 2 0
Unknown 7 0.2
Figure 2.3 overall lung Cancer Survival 
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Figure 2.4 overall Survival by Gender
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Figure 2.5 overall Survival of Smoking History by Gender
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Figure 2.6 overall post operative Survival by Stage
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2.2a Oesophageal and 
Oesophago-gastric Junction
summary Points
The NCCP announced in July 2012 that SJH 
is designated as both the National Centre 
for Oesophageal and Gastric Cancer and the 
National Centre for Management of Early Upper 
Gastrointestinal Mucosal Neoplasia (i.e. early 
tumours arising in Barrett’s Oesophagus). Professor 
John Reynolds has been appointed as the National 
Lead for oesophageal and gastric cancers. 
The key summary points in ongoing prospective 
audit are as follows:
• Based on NCRI figures, for years 2007-2010, 
approximately 65% of surgical resections for 
oesophageal cancer in Ireland are undertaken 
at SJH.
• 80% of all referrals are tertiary, testimony 
to its national role up to now and its recent 
designation as National Centre. 
•  Rapid Access clinics take place on Wednesdays 
and Thursdays, with major surgery performed 
on Mondays and Fridays.
• In 2012, 82 complex major upper 
gastrointestinal resections were  
performed, 50 for oesophagectomy,  
and 32 for total gastrectomy.
• Endoscopic surgery, particularly endoscopic 
mucosal resection (EMR) has increased 
in frequency, with 30 additional patients 
undergoing this procedure for early cancer. 
• The team over the time period of the audit 
includes Professor John Reynolds and  
Mr. Narayamasamy Ravi (surgeons); Professor 
Dermot O’Toole and Dr. Finbar Mc Carthy 
(specialist gastroenterology for endsoscopic 
ultrasound (EUS) and endoscopic resection 
(EMR); the late Professor Donal Hollywood  
and Dr. M. Cunningham (radiation oncology); 
and Professor Ken O’Byrne and Dr. S. Cuffe 
(medical oncology). Ms. Jennifer Moore is the 
Cancer Nurse Specialist.
• A major advance at the end of 2012 was the 
launch of the neo-AEGIS trial, led by SJH. This 
is an investigator-led international randomised 
trial comparing preoperative chemotherapy 
with preoperative chemotherapy and radiation 
therapy in patients with adenocarcinoma of the 
oesophagus and oesophago-gastric junction. 
The trial nurse co-ordinator at SJH is  
Ms. Geraldine Lee.
• Multidisciplinary model is well established,  
in particular for clinical trials of multimodality 
therapy and related molecular and  
scientific research.
• All oesophageal tumours biobanked for DNA 
and RNA research.
• TCD Departments of Surgery and Medicine have 
a long-established major focus on oesophageal 
disease, including oesophageal cancer and 
Barrett’s oesophagus, with grant income of 
approximately 5 million euro.
• The standards and performance indicators 
for oesophageal cancer are well inside 
internationally-accepted benchmarks in high 
volume centres: an in-hospital post-operative 
mortality of 2.5%, 1% in the last 100 cases  
(5-10% are international figures); integrated 
care pathways operational; and patients linked 
to the cancer clinical trials programme.
• Programme strengths include cognate tertiary 
services in thoracic and head and neck surgery, 
interventional radiology, critical care and 
medical gastroenterology.
• Defined linkage with St. Luke’s Hospital (SLH).
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In 2012, there were 25 clinical and research 
papers published from the oesophageal and 
gastric cancer programme.
oesophageal Cancer Trends
This report looks at 1426 oesophageal cancer 
patients diagnosed and/or treated in SJH from 
2003 to 2012. This shows the upward trend, with 
a 102% increase of oesophageal cancer patients 
presenting to SJH over the 10 year period.
Figure 3.1 oesophageal and Junctional 
cancer 2003-2012
Gender & age analysis
Gender analysis revealed oesophageal cancer 
incidence has remained stable at 32% female, 
and 68% male. Ages ranged from 20-97 years, 
and the median age was 67. 62% of patients 
were aged between 61 and 80 years.
Tumour site
Table 3.1 Tumour Site
Tumour site occurrences Percent
Upper 
Oesophagus
54 4%
Middle 
Oesophagus
284 20%
Lower 
Oesophagus
259 18%
OG Junction 821 57%
Post Cricoid 16 1%
66% of these cancers were adenocarcinoma 
morphology.
Clinical staging
Table 3.2 Clinical Stage
Clinical stage occurrences Percent
Stage 0/HGD 73 5%
Stage 1 156 11%
Stage 2 402 28%
Stage 3 375 26%
Stage 4 353 25%
Unable to assess 51 4%
Unknown 16 1%
Pathological staging (n = 538)
Table 3.3 pathological Stage
Pathology 
stage
occurrences Percent
Stage 0 57 11%
Stage 1 119 22%
Stage 2 147 27%
Stage 3 191 36%
Stage 4 24 4%
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Treatment options
The MDT conference aims to discuss oesophageal cancer patients in the presence of the members of 
the MDT. The purpose of this is to co-ordinate the sequence of treatment modalities. 95% of patients 
were discussed at the conference over the last 5 years.
Table 3.4 Treatment options for oesophageal Cancer
Treatment options for oesophageal Cancer occurrences* Percent
SURGERY 550 39%
Neo-adjuvant 343 24%
Radical Radiotherapy/Chemotherapy 148 10%
Adjuvant Chemotherapy/Radiotherapy 59 4%
Endomucosal Resection (EMR) 82 6%
Radiofrequency Ablation 46 3%
Chemotherapy alone 14 1%
Radiotherapy alone 20 1%
Endoscopic Dilatation 266 19%
Stenting 238 17%
Psychiatric Consult 40 3%
Palliative Care 325 23%
Palliative Chemotherapy 264 19%
Palliative Radiotherapy 118 8%
No Treatment/Surveillence only 26 2%
*Please note patients may have more than one treatment. 
62% (842) of patients were approached with curative intent.
survival 
The overall oesophageal cancer survival rate at 5 years is 22%. This rate includes oesophageal cancers 
diagnosed at all stages and treatment intents. For the 842 patients treated with curative intent the 
following graph shows actual survival, with 3 year survival at 47%. This rate is comparable with the 
UK’s 3 year survival of 43% for curative intent patients, published in their National Oesophao-gastric 
Cancer Audit 2012.
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Figure 3.2 Curative intent oesophageal Cancer survival
Survival time 0 years 1 year 3 years 5 years
No of patients 882 627 248 103
% Survival 100% 74% 47% 35%
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Figure 3.3 oesophageal Cancer survival by pathological node Stage (pn or ypn)
N0
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N3
Survival time 0 years 1 year 3 years 5 years
No at Patients 274 229 122 59
% Survival 100% 91% 79% 65%
Median survival N0 = 95 months
No at Patients 189 143 44 23
% Survival 100% 70% 29% 24%
Median survival N1 = 20 months
No at Patients 41 26 4 2
% Survival 100% 54% 18% 9%
Median survival N2 =15 months
No at Patients 32 25 4 2
% Survival 100% 78% 26% 26%
Median survival N3 = 19 months
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2.2b Gastric Cancer  
(excluding junctional)
Gastric Cancer Trends
The following report looks at 452 new gastric 
cancer patients diagnosed and/or treated in  
SJH 2003-2012. 
Figure 3.4 Gastric Cancer 2003-2012
Gender & age analysis
Gender analysis revealed gastric cancer incidence 
was 41% female and 59% male. Ages ranged 
from 21-95 years, and the median age has 
remained stable at 70 years. 57% of patients 
were aged between 61 and 80 years.
Clinical staging
Table 3.5 Clinical Staging
Clinical stage occurrences Percent
HGD 15 3%
Stage 1 61 14%
Stage 2 84 19%
Stage 3 70 15%
Stage 4 152 34%
Unable to assess 37 8%
Unknown 32 7%
The most common morphology was 
adenocarcinoma, accounting for 86%  
of all tumours.
Treatment options
Table 3.6 Treatment intent
Treatment 
intent
occurrences Percent
Radical 210 47%
Palliative 232 51%
Uncertain intent 7 1.5%
Unknown 2 0.5%
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Pathological staging (n = 166)
Table 3.8 pathological Stage
Pathology 
stage
occurrences Percent
Stage 0 6 4%
Stage 1 51 31%
Stage 2 47 28%
Stage 3 48 29%
Stage 4 14 8%
survival
The overall gastric cancer survival rate at 5 
years is 23%. This rate includes gastric cancers 
diagnosed at all stages and treatment intents. 
For the 210 patients treated with curative intent, 
the following graph shows actual survival, with 3 
year survival at 58%. This rate is comparable to 
the UK’s 3 year survival of 49% for curative intent 
patients, published in their National Oesophago-
gastric Cancer Audit 2012.
Table 3.7 Treatment options for Gastric Cancer
Treatment options for Gastric Cancer occurrences* Percent
SURGERY 167 37%
Neo-adjuvant 36 8%
Adjuvant Chemotherapy 24 5%
Endomucosal Resection (EMR) 14 3%
Chemotherapy alone 21 5%
Radiotherapy alone 8 2%
Endoscopic Dilatation 26 6%
Psychiatric Consult 8 2%
Palliative Care 155 34%
Palliative Resection 18 4%
Palliative Chemotherapy 107 23%
Palliative Radiotherapy 8 2%
No Treatment/Surveillence only 20 4%
Please note patients may have more than one treatment
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Figure 3.5 Curative intent Gastric Cancer survival 
 1 year 3 years 5 years 
 84% 58% 46% 
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Figure 3.6 Gastric Cancer survival by pathological node stage (pn or ypn)
 Five Year Survival Rate Median Survival   
68% 98 months  N0
30% 26 months  N1
28% 28 months  N2
31% 31 months  N3
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2.3 Skin Cancer
summary Points
There is an increasing burden of both 
melanoma and non-melanoma skin cancers 
(NMSC) in Ireland. There are approximately eight 
hundred new cases of malignant melanoma 
diagnosed in Ireland each year while the number 
of NMSC (primarily basal cell and squamous cell 
carcinomas) is approximately twenty to twenty-
five thousand per year, with approximately 7000 
new patients a year being diagnosed with their 
first tumour.
The delivery of skin cancer management in SJH 
is via an integrated, multidisciplinary model. 
The dermatosurgery unit in SJH is the only unit 
which provides a Mohs Micrographic Surgery 
service to public health patients in the Republic 
of Ireland. The unit consists of two consultant 
dermatologists who are fellowship-trained Mohs 
Micrographic surgeons.
The dermatosurgery unit provides a local and 
regional service for both melanoma and NMSC 
patients. It is also the tertiary referral centre for 
the management of complex and high-risk skin 
cancer patients. 
Suspected melanomas or squamous cell 
carcinomas are now triaged into rapid access 
clinics performed by both the dermatosurgery and 
plastic surgery services. “See and Treat” clinics 
have been developed to expedite management of 
these patients.
structure
The delivery of skin cancer care (in SJH) is 
through a closely integrated, multidisciplinary 
model. Management is optimised through the 
close cooperation between the following 
services: dermatosurgery, plastic surgery 
dermatopathology, E.N.T., and maxillofacial 
surgery. There are also close ties with the relevant 
oculoplastic services in the city. SJH is fortunate 
to have two of the four dermatopathologists 
in the country which greatly aids in the 
management of both melanoma and NMSC 
cases (Dr. Niamh Leonard and Dr. Mairin 
McMenamin). The programme is complimented 
by the role of SJH as the National Centre for 
Maxillofacial Surgery, and Burns, and its major 
head and neck and reconstructive programmes.
The Mohs Micrographic Surgery service was 
established by Dr. Patrick Ormond in 2006. 
Dr. P. Ormond was Chairman of the NCCP 
Programme for skin cancer, and a founding 
member of both the Irish Skin Foundation and 
the Irish Melanoma Forum. It provides a local 
and tertiary referral service. Currently, Mohs 
Micrographic Surgery is performed two and a 
half days a week. The recent appointment of 
a second consultant Mohs Micrographic Surgeon 
(Dr. Rupert Barry) enabled this increased activity. 
The service does not receive any dedicated 
funding and the expansion has resulted in an 
increased need for investment in both staffing 
and physical infrastructure in the short to 
medium term.  
Currently, the dermatosurgery unit provides a 
Mohs Micrographic Surgery service for patients 
with aggressive or high risk tumours. It also 
provides a skin cancer service for the cohort of 
immunosuppressed patients in the hospital (HIV, 
solid organ transplant recipients, haematology 
patients as well as those on immunosuppressive 
mediations), as well as those attending services 
elsewhere in Ireland. High risk patients, who are 
genetically predisposed to developing high risk 
skin cancers, such as the Epidermolysis Bullosa 
patients, are also closely followed by the MDT in 
dermatology.  
 
The Dermatology department is involved in 
the education of both undergraduate and 
postgraduate staff (SpR’s, regional nursing 
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staff, GPs). Three of the Department’s registrars 
have successfully obtained Mohs micrographic 
surgery fellowship in the UK and Canada. The 
dermatosurgery unit regularly presents at peer-
reviewed national and international meetings 
and has had recent publications in peer-reviewed 
international journals .Dr. R. Barry has spoken at 
the Annual Meeting of the American College of 
Mohs Surgeons and has been an invited speaker at 
the International Society of Dermatologic Surgery. 
Both Drs R. Barry and P. Ormond have been invited 
speakers and members of faculty at meetings of 
the British Society for Dermatologic Surgery.
skin Cancer Trends
This report examines both NMSC and 
melanomas from 2003-2012. There were over 
800 new patients diagnosed in SJH with NMSC 
in 2012, this represents a 110% increase in 
newly diagnosed NMSC patients over the last 
ten years. Please note that this figure represents 
new patients diagnosed and not new NMSCs 
diagnosed on a previously diagnosed patient. 
Therefore this doesn’t reflect the true workload 
of the department.
Figure 4.1 nmSC 2003-2012
Figure 4.2 melanomas 2003-2012
For melanoma, there has been a 124% increase 
in new diagnoses since 2003.
skin Cancer MDT
The first skin MDT in Ireland was established in 
April 2005. The team consists of a dermatologist 
as the lead clinician, a plastic surgeon, a 
dermatopathologist, a radiation oncologist 
medical oncologist, a maxillofacial  surgeon, 
and data manager. There is a 0.5 WTE MDT 
co-ordinator. Selected complex or inadequately 
excised NMSCs and all melanoma cases are 
discussed. 88% of all melanomas have been 
discussed at MDT since 2005. The Skin MDT in 
SJH is the only MDT in the country to include 
(and discuss) complex NMSC patients.
Table 4.1 melanoma mdT discussion
year Percent
2005 91%
2006 97%
2007 70%
2008 86%
2009 85%
2010 99%
2011 93%
2012 96%
Melanoma audit
There were 1117 new patients with 1142 
melanomas diagnosed and treated in SJH over 
the last ten year period. The average age at 
diagnosis was 60 years with a range from 13-98 
years. There has been little variation in the age 
of diagnosis over the ten year period. 58% of 
patients were female.
15% had a previous NMSC at the time of 
diagnosis. 9% had a previous melanoma 
or melanoma in situ. 6.5% had a previous 
malignancy, although this data is underestimated 
as this information is often unavailable in 
the patient’s history.
94% of patients were treated with curative 
intent. 98% of patients had a surgical excision 
as part of their primary treatment.
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Table 4.2 Tumour Site (n=1117, 1142 tumour sites)
39% of melanomas are found on the head and neck region.
Table 4.3 melanoma Type
occurrences Percent
Face 214 18.6
Posterior Trunk 154 13.4
Left Lower Limb 122 10.7
Right Lower Limb 107 9.3
Right Upper Limb 98 8.5
Left Upper Limb 86 7.5
Neck 57 5
Anterior Trunk 54 4.7
Forehead 73 6.4
Nose 34 3
Ears 32 2.8
Metastatic disease only (No primary found) 27 2.4
Scalp 25 2.2
Vulva 11 1
Eyelid 9 0.8
Lips 4 0.4
Anal 3 0.3
Eye 3 0.3
Penile 2 0.2
Other 19 2.2
Not specified 3 0.3
occurrences Percent
Superficial Spreading Melanoma 360 31.5
Lentigo Maligna/Melanoma in situ 348 30.5
Lentigo Maligna Melanoma 182 15.8
Malignant Melanoma-not specified 115 10.1
Nodular Melanoma 84 7.4
Acral Lentiginous Melanoma 25 2.2
Desmoplastic melanoma 9 0.8
Spindle cell melanoma 8 0.7
Other 11 1
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Table 4.4 Histological features of invasive tumours (n=779)
10-15% of patients were unknown histologies.
Table 4.5 Breslow depth 
 
50% of patients had a Breslow depth of less than 1mm at the time of presentation.
Histological features occurrences Percent
Ulceration 153 19
Mitoses present 364 46
Extra capsular spread 12 1.5
Perineural Invasion 24 3
Vascular Invasion 40 5
Regression 201 25
Tumour Infiltrating Lymphocytes
   Non Brisk 266 33.5
   Brisk 44 5.5
Microsatellites 5 4.6
Co-existent naevus 206 26
Breslow Depth occurrences* Percent
Tis (melanoma in situ) 321 28.1
<1  mm (T1) 365 32
1.01-2 mm  (T2) 132 11.6
2.01-4.0mm  (T3) 107 9.4
>4.0mm (T4) 128 11.2
Unknown/Not recorded 89 7.7
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Table 4.6 overall pathological Stage (n=1117, 1142 tumour sites)
12.6% of all patients present with stage 3-4 disease at the time of presentation. 222 (19.4%) patients 
had a sentinel node biopsy (SNB) at the time of diagnosis. Of that group, 35% were found to have a 
positive SNB. 91% of those went on to have a complete lymph node dissection. This analysis does not 
include patients who had a SNB or lymph node dissection for a suspected recurrence.
survival analysis
Figure 4.3 overall Survival by Breslow depth (Cancer free survival)
 
T0
T1
T2
T3
T4
Survival time 0 years 1 year 3 years 5 years
No at Patients 321 275 204 126
% Survival 100% 99% 99% 99%
No at Patients 365 322 200 113
% Survival 100% 100% 98% 98%
No at Patients 132 122 75 45
% Survival 100% 100% 96% 89%
No at Patients 107 92 58 37
% Survival 100% 97% 83% 77%
No at Patients 128 95 43 24
% Survival 100% 85% 66% 49%
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Pathological stage occurrences* Percent
Stage 0 342 29.9
Stage Ia 266 23.3
Stage Ib 175 15.3
Stage IIa 75 6.6
Stage IIb 43 3.8
Stage IIc 57 5
Stage II 3 0.3
Stage IIIa 41 3.6
Stage IIIb 23 2
Stage IIIc 27 2.4
Stage III 8 0.7
Stage IV 43 3.9
Not recorded/Unknown 38 3.2
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2.4 Head & Neck Cancer 
structure
Head and Neck cancer patients within SJH  
are taken care of by two main teams,  
the Otolaryngology-Head & Neck Surgery  
and Maxillofacial Surgery, which ensures  
that patients in this group have access to  
the combined surgical strength of  
both departments.
The patient treatment pathway benefits from 
the combined academic strength of two Trinity 
College Professors of Surgery (Professor Conrad 
Timon and Professor Leo Stassen) and from the 
academic focus of the Department of Pathology 
in TCD (Professor John O’Leary, Professor Orla 
Shiels and Dr. Mary Toner). There is a linkage with 
AMNCH through a single department structure, 
(headed by Mr. John Kinsella) and agreement that 
all complex major cancer surgery is performed 
at SJH. There is also a co-operation with Dublin 
Dental School (DDS) and SJH for the management 
of oral cancers. All major surgery is undertaken at 
SJH and is managed by Professor Stephen Flint/
Dr. Marie-Louise Healy (Oral Medicine), working 
closely with Dr. Mary Toner (Oral Pathology) who 
is a joint appointment between the DDS and SJH. 
Surgery for this group of patients is complex and 
difficult, often requiring multiple surgical teams  
to play a part. A cancer centre model of 
combined multi-surgeon operations is in use  
for the most complex cases, with close interface 
with the plastic and reconstructive team, the 
oesophageal team, and the thoracic service.
Multidisciplinary team meetings
Weekly Head and Neck MDT meetings 
commenced in March 2006. Meetings are 
attended by all relevant stake holders and offer 
immense value to both patients and clinicians. 
From the clinician’s point of view they provide 
a forum of support and advice from peers to 
discuss difficult cases and to gain consensus on  
a pathway of care. For patients the meeting 
ensures that their treatment is based on 
the combined experience of all the relevant 
consultants present who bring all of their 
academic research and experience to bear on 
their decisions. Surgical decisions are determined 
by combined opinion of Prof. C. Timon,  
Mr. J. Kinsella, Mr. Paul O Neill, Prof. L. Stassen 
and Mr. Padraig O’Ceallaigh. Two specialist nurses 
are also present, Ms. Catherine O’Farrell and 
Ms. Joanne McDonagh. Radiation oncology is 
represented by Dr. S. Brennan. Radiology provides 
a large input on the decision making process with 
the majority of patients having PET/CT imaging  
prior to surgery.
Head and neck Cancer Trends
Outcome data for Head and Neck is not available 
at this time due to maternity leave. A full report 
for Head and Neck cancer will be available in 
2014. 
There were 1964 new Head and Neck cancer cases 
(ICD C01 -14, C30-32, C73.9) diagnosed and/
or treated in SJH between 2003 and 2012, with 
an average of 196 new patients per year. A year 
on year increase in the total numbers is noted 
with a percentage increase of 123% over the 10 
year period. A total of 259 head and neck cancer 
patients were diagnosed and/or treated in 2011 
with 285 diagnosed in 2012. The latest available 
national figures from the NCRI show that there 
were an average of 523 head and neck cancers 
diagnosed nationally between 2008 – 2010 which 
suggests that the Head and Neck cancer team in 
SJH treated almost 41% of this group.
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Head & Neck cancers affect more males than 
females. In its latest report the NCRI data1  
showed that over a 17 year period (1994 – 2010) 
the ratio of men to women was almost 1.7:1. 
Over a 5 year period in SJH (2007 – 2012) the 
ratio of men to women was similar at 1.8:1.
1. Cancer in Ireland 2013: Annual Cancer Report of the National 
Cancer Registry.
Table 5.1 Breakdown of male  
vs. Female Cancers
year Men women
2003 87 41
2004 92 61
2005 101 64
2006 90 61
2007 117 66
2008 125 70
2009 135 70
2010 161 79
2011 155 104
2012 189 96
Figure 5.2 age analysis at diagnosis 
The age distribution of the SJH group (see fig 5.2) 
reflects the pattern of the NCRI, with the average 
age over a 10 year period in the NCRI being 63 
years. The average age of patients in SJH is 60 
years.
Figure 5.1 newly diagnosed Head & neck Cancer 2003 - 2012
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2.5 Colorectal Cancer
service
• The colorectal service is involved in the 
management of over 9% of the national 
colorectal cancer workload. 
• There is a well-developed multimodal  
treatment model for rectal cancer, with 
integrated staging, treatment planning,  
audit and follow-up. 
• SJH is a high volume centre for colorectal 
diseases, with laparoscopic surgery the 
preferred approach within the Unit. 
• All colorectal cancer cases are discussed at 
a weekly MDT conference where the most 
appropriate treatment modality is proposed  
for the individual patient.
• Our rates for sphincter preservation, 
anastomotic leaks, in-hospital morbidity and 
mortality, and stage for stage survival are 
consistent with international benchmarks. 
• Our standards are defined and linked with the 
Association of Coloproctology of Great Britain 
and Ireland (ACPGBI), and audit shared with 
and accredited to this Association.
• There is close alignment with gynaecology 
oncology and urological oncology services. 
Colorectal service structure
• Colorectal Consultant Surgeons, Mr. Richard 
Stephens (retired), Mr. Robert Quill (retired)  
Mr. Brian Mehigan and Mr. Paul McCormick 
provide specialised joint care to all in-patients, 
working as an integrated team with senior 
and junior registrars in the GEMS Directorate. 
This team based care includes ward rounds, 
operating lists and flexible out-patient clinics. 
• Two senior specialist registrars work in a level  
3 colorectal training post as approved by  
the ACPGBI.
• Consultant oncologists, Professor Peter Daly 
(retired) Prof. J. Kennedy and Professor Kenneth 
O’Byrne (has left SJH service), provide specialised 
oncology care for patients with colorectal cancer 
including involvement in new chemotherapy 
trials. The medical oncology service is also 
supported by a colorectal oncology liaison nurse. 
• The Consultant Radiation oncology service was 
initially provided by the late Prof. D. Hollywood 
and Dr. C. Gillham joined the service in 2008 
providing specialised radiation oncology 
care for patients with colorectal cancer. The 
radiation oncology service is also supported by 
a radiation liaison nurse. 
• Specialist GI Cancer Consultant Histopathologists, 
Dr. D.Sean O’Briain, Professor Eoin Gaffney, Dr. 
Cian Muldoon, Dr. Stephen Finn and Dr. Richard 
Flavin review all colorectal specimens and 
histology.
• Consultant Radiologists, Prof. M. Keoghan,  
Dr. C. Johnson, Prof. J. Meaney, Dr. N. Sheehy, 
Dr. P. Beddy and Dr. G. Wilson have expertise  
in colorectal cancer staging providing 
radiological services.
• Consultant Gastroenterologists, Prof. P. Keeling 
(retired), Professor Donald Weir (retired), 
Professor Nasir Mahmud, Dr. Susan McKiernan, 
Prof. Suzanne Norris, Professor Dermot O’Toole 
and Dr. Finbarr MacCarthy; provide diagnostic 
and therapeutic endoscopic services, including 
endoscopic ultrasound, to colorectal cancer 
patients.
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• Palliative Care Consultants Dr. Liam O’Siorain 
(has left SJH Service), Dr. Peter Lawlor (has left 
SJH Service), Dr. N. O’Leary and Dr. L. Balding 
provide in-patient and out-patient palliative 
care services to colorectal cancer patients. 
The service is also supported by Palliative Care 
clinical nurse specialists.
• Liaison Psychiatry Consultants Dr. AM. O’Dwyer, 
Dr. J. Cooney and Dr. S. Collier provide 
psychiatric services and access to psychological 
support services.
• Dr. D. Gallagher and Prof. A. Green provide genetic 
counselling services to patients with a personal or 
family history suggestive of an underlying inherited 
predisposition to colorectal cancer. 
• The GI Function Lab provides rectal manometry 
to appropriate colorectal cancer patients. 
• Full time colorectal nurse co-ordinators,  
Ms. Delia Flannery and Ms. Katrina O’Connor 
facilitate the management and support of 
the colorectal cancer patient as they follow the 
pathway through referral, diagnosis, treatment  
and follow-up.
• Stoma care clinical nurse specialists,  
Ms. AnneMarie Stuart (full time) and  
Ms. Anna Fearon and Ms. Siobhan McGovern 
(job sharing), review all patients that may 
potentially require a stoma during planned 
surgery. They provide in-patient and out-patient 
education and counselling for colorectal cancer 
patients who have had a stoma formed.
• Full time colorectal data manager, Ms. Charlotte 
Stuart, ensures full prospective collection of  
all patient parameters, carries out regular  
audit and provides data for research and  
reporting purposes. 
Colorectal service Process 
• An average of 4 colorectal OPD clinics per week.
• An average of 5 specialised colorectal 
endoscopy sessions available per week.  
There are 2 x-ray rooms to facilitate colonic 
stenting and 1 endoscopic ultrasound room.
• 7 theatre sessions weekly.
• There is 1 day surgery session per week.
• Access to regular in-patient and out-patient  
x-ray facilities, for example: MRI scans  
(2 weekly dedicated appointment slots),  
CT scans (2 weekly dedicated appointment 
slots), Rectal and anal ultrasound, Barium 
studies, PET scans and CT Colonography  
are available for colorectal cancer patients.
• Access to once weekly sessions on  
rectal manometry.
Colorectal services and  
Quality assurance
• Once weekly MDT meetings which are 
organised by experienced MDT co-ordinators, 
provide a structured and co-ordinated 
approach to the delivery of cancer care. The 
MDT meeting is attended by a Consultant 
Liver Surgeon from St. Vincent’s Hospital on 
a fortnightly basis. The meeting links with 
Tullamore General Hospital allowing discussion 
of their cancer patients. 
• A full range of open, laparoscopic and 
transanal resectional surgery with, where 
necessary, pouch reconstruction, is practiced  
in the colorectal unit.
• Colonic stenting is provided as a bridge to surgery 
for patients presenting with obstructing tumours 
and for palliation of obstructive symptoms. 
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• A Colorectal Cancer Care Pathway is in place using 
evidence based research and guidelines from the 
ACPGBI and is regularly reviewed and updated. 
• Colorectal cancer data is submitted annually for 
inclusion in the National Bowel Cancer Audit 
which was developed by the ACPGBI and is 
correlated and managed by the Clinical Audit 
Support Unit in the NHS in England. 
• A weekly nurse-led follow up clinic for patients 
who have curative surgery for colorectal cancer. 
The follow up clinic provides a more complete 
and accurate patient follow up in a patient 
focused environment.
• An electronic colorectal cancer database, in 
place since 2001, enables the capture of all 
information relating to the patient journey, 
including referral, diagnosis, treatments and 
follow-up ensuring quality assurance. 
• The stoma care department run a bi-annual 
Stoma Foundation course for staff nurses 
within the hospital. This course is category 1, 
An Bord Altranis approved. 
• The stoma care department work closely with 
UCD providing education to the post graduate 
colorectal oncology students whilst  
on placement in SJH.
• 2011 saw the introduction of stoma care pre 
admission clinics; which aims to reduce patient 
stress and anxiety by offering the most up to 
date information regarding treatment in  
a patient focused setting.
• The second patient satisfaction survey is 
underway to assess the service being provided 
by the Nurse Led CRC Follow-Up clinic. 
• Development of an Enhanced Recovery 
after Colorectal Surgery programme. This 
programme was launched in April 2013. The 
principle of ERAS is to enable the patient to 
have a more rapid recovery from surgery in 
order to leave hospital sooner by minimising 
the stress responses on the body during 
resection surgery.
• The Key Performance Indicator programme  
for colorectal cancer was introduced in 2010  
to measure the timeliness of access to  
services, investigations and treatment of 
colorectal cancer patients. These standards  
are under regular review at quarterly KPI 
meetings to ensure their suitability and  
to measure compliance.
• Ms. Delia Flannery, CRC Co-ordinator and  
Ms. AnneMarie Stuart, Stoma Care CNS,  
have successfully completed a level 9 post 
graduate diploma in colorectal cancer nursing. 
Ms. Katrina O’Connor, CRC Co-ordinator  
began this course in September 2013.
• The colorectal team are currently trialling day of 
surgery admission for colorectal cancer patients 
which includes a colorectal pre admission 
clinic supported by the CRC Consultants, 
Anaesthetists and co-ordinated by the CRC 
nurses and the Day Surgery CNS’s.
• Colorectal Cancer Screening has commenced 
in SJH offering free screening to men and 
women aged between 55-74 years. The service 
is supported by the screening CNS, Ms. Linda 
Foy, who assesses patient’s suitability for 
colonoscopy and guides them through the 
screening process. 
CrC audit 2003-2012
During the period 2003 to 2012 a total of 1,708 
patients were referred to, diagnosed with and/
or treated in SJH for colorectal cancer. This report 
focuses in detail on 1,453 of these patients 
referred to or diagnosed in SJH with colorectal 
cancer who had full treatment; surgery alone or 
adjuvant therapy. The remaining 255 patients 
were referred specifically for the opinion of the 
GI oncology MDT, a small percentage of patients 
were referred for lung resection, chemotherapy or 
palliative care for recurrence of colorectal cancer 
having been initially diagnosed and  
treated elsewhere. 
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Colorectal cancer includes malignant tumours 
of the appendix, colon, rectum and anus. 
Approximately three new cases of colorectal 
cancer are diagnosed or referred to SJH weekly. 
This accounts for almost 6% of the total SJH 
cancer workload and 8% of the national 
workload (NCR 2012).
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Colorectal Cancer Trends
Since 2003, there has been a 43% increase in the 
number of new patients referred to the colorectal 
cancer service in SJH.
Figure 6.1 Colorectal Cancer 2003-2012
Gender & age analysis
Gender analysis revealed colorectal cancer 
incidence was 42% female and 58% male. 
Colorectal cancer incidence is more common  
in the over 75 age group and 34% of patients  
fell within this category. The average age of 
patients at time of diagnosis was 67.37 years. 
Ages ranged from 16 to 99 years and the  
median age was 69. Approximately 83% of 
patients were aged between 55 and 99 years.
Tumour site
The vast majority of colorectal cancers  
are moderately differentiated (75%) 
adenocarcinomas (90%), with the most  
common sites for tumour occurrence being  
the rectum (33%) and the sigmoid colon (19%).
Table 6.1 Tumour Site (2003-2012)
no. of 
Tumours*
Percent
Rectum 490 33%
Sigmoid colon 288 19%
Caecum 175 12%
Ascending colon 110 7%
Transverse colon 82 6%
Rectosigmoid 82 6%
Hepatic flexure 59 4%
Descending colon 55 4%
Splenic flexure 47 3%
Appendix 43 3%
Anus 31 2%
Site not specified 14 1%
Small bowel 9 1%
Terminal ileum 5 <1%
*Some patients may have synchronous tumours.
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Treatment options
The focus on a multidisciplinary approach to 
patient care has seen patients discussed at the 
weekly MDT conference increase by 286% 
since 2003. The MDT facilitates the planning 
and co-ordination of the sequence of treatment 
modalities. Treatment options for colorectal 
surgery can be seen in the table below. 
Table 6.2 Treatment options  
2003–2012
Colon Cancers rectal Cancers
Surgery 657 350
Chemotherapy 398 276
Non resection 
surgeries* 230 265
Radiotherapy 49 254
Endoscopic 63 21
No treatment 63 20
Colonic Stent 48 12
Note: Treatments are not mutually exclusive.
*Some patients may have multiple surgeries including stoma 
formation/stoma reversal.
Colon Cancers
• Colon cancer patients were treated with  
a curative intent in 67% of cases.
• Metastatic disease was present in 27%  
of patients at time of diagnosis.
• Prior to 2008 10% of all colon cancer resection 
surgeries were laparscopic; this figure has 
increased to 58% for the last 5 years. 
• Anastomotic leak rate is 2.9%. (Based on 580 
anastomosis formed).
• Median lymph node harvest was 15.
rectal Cancers
• Rectal cancer patients were treated with  
a curative intent in 73% of cases.
• Metastatic disease was present in 18%  
of patients at time of diagnosis.
• 202 patients had neoadjuvant therapy prior  
to rectal cancer resection.
• Prior to 2008 6% of all rectal cancer resection 
surgeries were laparscopic; this figure has 
increased to 56% for the last 5 years. 
• Anastomotic leak rate is 5.8%. (Based on  
222 anastomosis formed).
• APER rate is 23.9%. (ACPGBI recommend  
it to be <30%).
• Median lymph node harvest was 12.
lead Times 
Lead times are recorded for use as a clinical 
indicator of a quality service:
• 83% of urgent referrals were seen within 1 month.
• 87% of patients were diagnosed within a 
month of initial referral.
• 70% of patients started their treatment  
within a month of diagnosis.
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Figure 6.2 Colon Cancer Survival by Treatment intent
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 % Survival 100% 91% 78% 70%
Palliative No at Patients 276 113 20 5
 % Survival 100% 41% 12% 4%
Figure 6.3 rectal Cancer Survival by Treatment intent
Year
 Survival time 0 years 1 year 3 years 5 years
Curative No at Patients 356 298 193 102
 % Survival 100% 95% 84% 71%
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2.6 Gynaecological Cancer
Gynaecological cancer care at SJH is accredited 
by the NCCP as a regional and national referral 
centre for the care of women with genital tract 
malignancies. The gynaecological surgical  
facility at SJH is now dedicated exclusively to  
the provision of care of women with cancer  
and those with complex benign diagnoses.  
This arrangement has been facilitated by our 
sister Trinity gynaecological units at the Coombe 
Women’s & Infants’ University Hospital (CWIUH), 
Adelaide Meath/Tallaght (AMNCH) and a robust 
referral mechanism has been developed. 
The Colposcopy service is located at CWIUH 
& AMNCH. Dr. Tom D’Arcy is director of 
the colposcopic/pre-invasive cervical cancer 
programme for the Trinity Hospitals. 
The GynaeOncology Division has three 
subspecialist trained surgical gynaecological 
oncologists, Dr. Noreen Gleeson, Dr. T. D’Arcy.  
Dr. Waseem Kamran (locum tenens). Specialist 
medical oncologist for gynaecological cancers 
is Dr. Dearbhaile O’Donnell. Specialist radiation 
oncologist for gynaecological cancers is  
Dr. Charles Gillham.
Clinical nurse specialists in gynaecological cancer 
care are Ms. Debra McKnight and Ms. Ciara 
Donohoe. Data management is completed by  
Ms. Therese Brown.
Minimal access (laparoscopic) approach to  
surgery is standard of care for cervical and 
endometrial cancers. The gynaecological  
oncology division supports the genetic breast/
ovary clinic with a risk reduction surgical service. 
The three gynaecologic oncologists are 
subspecialist trainers and the training programme 
is approved by the Royal College of Obstetricians 
& Gynaecologists (RCOG). SJH is the only unit in 
the republic of Ireland that is RCOG accredited for 
senior fellowship training. The large case volume 
and increasingly more complex clinical caseload in 
a multidisciplinary setting provides a high quality 
training framework. 
Research is undertaken in conjunction with 
ICORG/GCIG for clinical trials and TCD for 
basic science/laboratory projects. The basic 
science facilities are directed by Professor John 
O’Leary, Dr. Lucy Norris & Dr. Sharon O’Toole. 
The research activity includes gynaecological 
cancer biology, pathology, coagulation, genomics 
and oncometabolomics. Basic science research 
fellowships are available for clinicians in training. 
The gynaecological cancer care programme is 
based around a weekly multidisciplinary conference 
that is attended by all relevant specialists. 
Table 7.1 Gynaecological Cancer  
mdT discussion
2006 2007 2008 2009 2010 2011 2012
93% 93% 92% 96% 95% 96% 98%
Gynaecological Cancer Trends
There were 2262 new gynaecological cancer 
patients diagnosed and/or treated in SJH over 
the last ten years. This figure includes 33 patients 
with more than one tumour site. Over this ten 
year period there has been an 86% increase in 
the gynaecological oncology service workload 
(See table 7.2). 
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The following is a breakdown of patients diagnosed and treated in SJH for the years 2003 to 2012. 
There were 32 patients with two tumour sites, and one patient with three tumour sites. The 2262 
newly diagnosed patient’s tumour sites are divided as follows. 
Table 7.2 SJH 10 year Gynaecological Cancer data by year by tumour site
Tumour site 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
Cervix 54 40 56 53 71 60 78 79 83 61 635
Ovary 57 69 66 61 55 84 95 93 93 94 767
Endometrium 35 26 40 56 52 78 88 100 88 111 674
Vulva 6 9 8 11 9 14 14 8 17 15 111
Others 8 9 10 17 10 7 12 8 12 16 109
Total 160 153 180 198 197 243 287 288 293 297 2296
Table 7.3 SJH figures as a percentage of national Gynaecological malignancies
Tumour site 2003 2004 2005 2006 2007 2008 2009 2010 2011
Cervix 27% 20% 22% 23% 24% 23% 22% 24% 26%
Ovary 15% 21% 20% 17% 17% 24% 27% 26% 28%
Endometrium 12% 9% 12% 18% 15% 20% 20% 24% 20%
Vulva 17% 19% 21% 21% 20% 29% 26% 19% 37%
SJH accounts for a significant amount of the national workload with approximately one quarter of all 
gynaecological malignancies diagnoses or treated in SJH.
Figure 7.1 Gynaecological Cancers by Tumour Site
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Cervix Uteri
There were 635 new cervical cancers diagnosed in 
this period. The median age was 53, and the age 
range was from 22 years to 98 years.
Table 7.4 Cervical Cancer  
– morphology
Morphology Type Percent
Squamous Cell Carcinoma 69
Adenocarcinoma 18
Adenosquamous 4
Other/Unknown 9
ovarian Cancer
There were 767 new ovarian cancers diagnosed 
in this period, including 138 of which were 
Borderline. The median age was 53, and the age 
range was from 15 years to 95 years.
Table 7.5 ovarian Cancer  
– morphology
Morphology Type Percent
Adenocarcinoma 22
Papillary Serous 34
Borderline 18
Clear Cell 7
Other/Unknown 19
Uterine/endometrial Cancer
There were 674 new endometrial (uterine corpus) 
cancers diagnosed in this period. The median age 
was 63, and the age range was from 27 years to 
94 years.
Table 7.6 endometrial/uterine Cancer 
– morphology
Morphology Type Percent
Endometrioid 
Adenocarcinoma
58
Adenocarcinoma 21
Papillary Serous 6
Other/Unknown 15
Vulval Cancer
There were 111 new vulval cancers diagnosed in 
this period. The median age was 59, and the age 
range was from 24 years to 88 years.
Table 7.7 Vulval Cancer – morphology
Morphology Type Percent
Squamous Cell Carcinoma 74
Melanoma 8
Other/Unknown 18
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Treatment Details
Cancer treatments for patients in 2012 are summarised below for each tumour site.
Table 7.8 Treatment details of Gynaecological Cancers (2012)
Cervix (n=61)  occurrences Percent 
None 1 1.6
Surgery Only 14 23
Surgery with adjuvant Radiotherapy 7 11.5
Surgery with adjuvant Chemoradiotherapy 7 11.5
Radiotherapy 10 16.4
Chemotherapy 3 4.9
Palliative Care/Best Supportive Care 3 4.9
Chemoradiotherapy 15 24.6
Unknown 1 1.6
ovary (n=94) occurrences Percent
None 1 1.1
Surgery Only 32 34
Surgery with adjuvant chemotherapy 36 38.3
Surgery with adjuvant radiotherapy 1 1.1
Surgery with adjuvant chemoradiotherapy 1 1.1
Chemotherapy 7 7.4
Palliative care/best supportive care 1 1.1
Primary Chemotherapy with adjuvant Surgery 14 14.9
Unknown 1 1.1
endometrial (n=111) occurrences Percent
None 2 1.8
Surgery Only 54 48.6
Surgery with adjuvant chemotherapy 8 7.2
Surgery with adjuvant radiotherapy 25 22.5
Surgery with adjuvant chemoradiotherapy 8 7.2
Radiotherapy 1 0.9
Chemotherapy 3 2.7
Palliative care/best supportive care 4 3.6
Primary Chemotherapy with adjuvant Surgery 2 1.8
Unknown 4 3.6
Vulva (n=15) occurrences Percent
Surgery Only 9 60
Surgery with adjuvant radiotherapy 4 26.7
Surgery with adjuvant chemoradiotherapy 1 6.7
Chemoradiotherapy 1 6.7
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survival analysis by Tumour site
Figure 7.2 Survival analysis of Cervical Cancer
Figure 7.3 Survival analysis of ovarian Cancer
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Figure 7.4 Survival analysis of uterine Cancer
Figure 7.5 Survival analysis of Vulval Cancer
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2.7 Urology Cancer
structure
• Well developed MDT approach to urological 
cancers provided by Professor Thomas Lynch,  
Mr. Ted McDermott and Mr. Rustom Manecksha 
(Mr. Ronald Grainger retired in 2012).
• The service is supported by a high standard 
of nursing care to patients by four CNS’s in 
Urology; Ms. Marion O’Brien, Ms. Lynn Casey, 
Ms. Sonya Bowen and Ms. Tanya Conroy.  
Ms. L. Casey is currently undertaking an MSc.  
in Advanced Nursing Practice.
• Consultant Oncologist, Dr. D. O’Donnell 
provides specialised oncology care for  
patients with urology cancer.
• Consultant Radiation Oncologists, Dr. N. 
Elbeltagi and Dr. M. Cunningham provide 
specialised radiation oncology care for patients 
with urology cancer. The radiation oncology 
service is also supported by a radiation  
liaison nurse. 
• High volume radiological input from the 
department of diagnostic imaging.
• SJH was the first hospital to offer laparoscopic 
surgery for urological malignancies.
• Academic unit led by Prof. T. Lynch with a 
special interest in laboratory based research 
in prostate cancer with a close working 
relationship to the Institute of Molecular 
Medicine (IMM) and the Conway Institute.
• Majority of prostate cancers biobanked for 
DNA and other research projects. Urine and 
blood also biobanked from patients undergoing 
prostate biopsies.
• Recognised centre for higher specialist training 
in urology surgery.
• SJH has been established as one of eight 
National Rapid Access Prostate Clinics (RAPC) 
in Ireland. These clinics provide rapid access to 
a prostate clinic where they will be assessed by 
an Urologist and will have access to a Urology 
CNS. The clinics have been established in an 
effort to speed up the process of referring 
men with a possible prostate cancer, to bypass 
waiting times for out-patient clinics and to 
provide access to prostate biopsy more quickly 
for those who need it.
• There are two RAPC each week and three  
‘one stop’ haematuria clinics.
• All cases discussed at MDT have access to 
special palliative care and psychological 
oncology services if required.
Urology Cancer Trends
There were 2717a urology cancers diagnosed 
and/or treated in SJH between 2003 and 2012. 
The Urology service is the second largest service 
in SJH. There has been a 248% increase in new 
urology cancers diagnosed and/or treated in this 
ten year period with a 464% increase in prostate 
cancer alone.
a Some patients had 2 synchronous urology cancers. 
75
Prostate Cancer
The RAPC was established in SJH in 2008. 
Audited data was submitted to the NCCP mid 
2010 and figures listed in table 8.1 are for the 
years of 2011 onwards. Ninety nine per cent of 
all patients referred to the service are offered an 
appointment within the guidelines specified by 
the NCCP of 20 working days. Based on 2011 
RAPC activity, SJH accounts for 14% of the 
national RAPC activity. Approximately 180  
new cancers are diagnosed with cancer from  
the RAPC service annually. 
Table 8.1 rapC activity 2011-2012
Clinic details 2011 2012
No. of new patients 361 363
No. of return patients 357 358
Total patients 718 721
No of clinics 86 93
new cancer diagnoses 187 180
Recurrent cancers 2 1
Other diagnoses, e.g. ASAPc 17 15
c Atypical Small Acinar Proliferation
In the ten year period, there were 1536 prostate 
cancer patients diagnosed and/or treated in 
SJH. The average age at diagnosis is 66 with 
men diagnosed from ages 39 to 99 years. The 
average age at diagnosis has reduced over the 
ten years from 70 to 65 years. SJH accounts for 
approximately 9% of national prostate cancer 
activity (based on 2010 data – latest available 
from NCRI).
The Urology MDT commenced in 2007 and the 
numbers discussed at MDT continue to increase 
year-on-year.
Table 8.2 prostate mdT activity by year
2007 2008 2009 2010 2011 2012
55% 66% 70% 79% 83% 86%
Table 8.3 Gleason Score (GS) 
prognostic Grade  
(epstein Grading System)b
Gleason Prognostic Grade occurrences %
Prognostic Grade I (GS</=6) 305 19.9
Prognostic Grade II (GS 3+4=7) 560 36.5
Prognostic Grade III (GS 4+3=7) 199 13.0
Prognostic Grade IV (GS=8) 180 11.7
Prognostic Grade V (GS 9-10) 157 10.2
Not recorded/Unknown 135 8.7
b  Prognostic Gleason grade grouping: data - based on the modified 
Gleason scoring system – Epstein, JI. BJU Int. May 2013.
Figure 8.1 urology Cancers 2003-2012 by Tumour Site
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Almost half of patients had a GS of seven (49.5%) (See table 8.3). Over half of patients had a clinical 
stage 1-2.
Table 8.4 prostate Cancer Clinical Stage
Clinical stage occurrences Percent
Stage I 179 11.6
Stage II 627 40.8
Stage III 304 19.8
Stage IV 159 10.4
Unknown/Not specified 267 17.4
Sixty one per cent were treated with curative intent. Fifteen per cent were started on an active 
surveillance program. Overall, 19% had palliative treatment. The remaining patients with unknown 
intent were often diagnosed in SJH and followed up privately or in the referring hospital. 
Table 8.5 planned primary Treatment options
Planned Treatment options occurrences Percent
None 9 0.6
Radiotherapy and Hormone therapy 538 35.2
Surgery only (Prostatectomy only) 328 21.4
Active surveillance/Active monitoring* 226 14.8
Hormone therapy only 200 13
Radiotherapy only (External beam  
or Brachytherapy)
55 3.6
Surgery and adjuvant Radiotherapy 48 3.1
Palliative Care - Best Supportive Care 19 1.2
Palliative Chemotherapy and  
Hormone Therapy
5 0.3
Surgery and adjuvant Hormone Therapy 5 0.3
Neoadjuvant Hormone therapy_ Surgery 
and adjuvant Radiotherapy
3 0.2
Surgery and neoadjuvant Chemotherapy 3 0.2
Hormone therapy_ Radiotherapy and 
Brachytherapy boost
1 0.1
Surgery and neoadjuvant Hormone 
Therapy
1 0.1
Surgery and neoadjuvant Chemotherapy/
Radiotherapy
1 0.1
Palliative Radiotherapy 1 0.1
Unknown/Not stated 88 5.8
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During this ten year period, the percentage of patients having curative treatment remained similar, 
although the percentage of patients starting out in an *active surveillance programme increased from 
4% in 2003 to 24% in 2012. In this ten year period, 478 patients underwent surgery for their prostate 
cancer, either radical surgery or a TURP. A breakdown of their surgery type is seen in table 8.6.
Table 8.6 prostate surgery Type (n=478)
Prostate surgery occurrences Percent
Prostatectomy 351 73.4
TURP 102 21.3
Cystoprostectomy 16 3.3
Other 4 0.9
Unknown 5 1.1
For the prostatectomy and cystoprostatectomy patients the following table lists the breakdown of 
pathology stage (table 8.7).
Table 8.7 pathology Stage (n=367)
Pathology stage occurrences Percent
Stage I 12 3.3
Stage II 264 71.9
Stage III 62 16.9
Stage IV 3 0.8
Unknown 26 7.1
Overall survival is used for prostate cancer patients which includes 179 patients who died for reasons 
other than their prostate cancer.
Figure 8.2 prostate cancers by intent
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Figure 8.3 prostate cancers by prognostic Gleason Grade (epstein 2013)b
Figure 8.4 prostate Cancer survival by pathological Stage (cancer specific survival)
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 Survival time 0 years 1 year 3 years 5 years
p Stage I No at Patients 12 9 7 4
 % Survival 100% 100% 100% 100%
p Stage II No at Patients 264 238 118 84
 % Survival 100% 100% 99% 99%
p Stage III No at Patients 62 54 24 15
 % Survival 100% 100% 100% 100%
p Stage IV No at Patients 3 3 2 1
 % Survival 100% 100% 100% 100%
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Kidney Cancer (515 patients, 525 tumour sites)
SJH is a major tertiary referral centre for treatment of kidney cancers with over 60% diagnosed 
elsewhere and referred to SJH for treatment. It was the first hospital to offer laparoscopic surgery  
for kidney cancer nationally. There has been a 250% increase in kidney cancers over this time period.  
The average age at diagnosis was 63 years with a range of 22-95 years. The average age at diagnosis 
has remained similar over this ten year period. Over one third were found incidentally and this has 
become more apparent in the last five years. Approximately two-thirds of all diagnoses were male.
Sixty per cent had treatment of curative intent. Approximately 5% started on an active  
surveillance programme. 
Table 8.8 planned primary Treatment options (515 patients)
Treatment options occurrences Percent
None 2 0.4
Surgery only 322 62.5
Minimally Invasive Treatment (Embolisation/RFA) 43 8.4
Radical Nephrectomy + adjuvant Systemic Therapy 31 6.0
Systemic Therapy 29 5.6
Active surveillance/Active monitoring 28 5.4
Palliative Care - Best Supportive Care 27 5.2
Palliative Radiotherapy 11 2.1
Surgery and Neoadjuvant Chemotherapy 4 0.8
Palliative Radiotherapy/Systemic Therapy 2 0.4
Hormone therapy only 2 0.4
Surgery and adjuvant Radiotherapy 2 0.4
Unknown/Not stated 12 2.4
Table 8.9 Kidney surgery Type (n=374)
Type of surgery occurrences Percent
Open Nephrectomy (full or partial) 134 35.9
Laparoscopic Nephrectomy 190 50.8
Laparoscopic Nephrectomy (Partial) 30 8.0
Laparotomy 8 2.1
Other 12 3.2
Table 8.10 Pathology stage (n=381)
Pathology stage occurrences Percent
Stage I 184 48.3
Stage II 45 11.8
Stage III 87 22.8
Stage IV 33 8.7
Unknown/Not specified 32 8.4
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Figure 8.5 overall Kidney Cancer survival 
Figure 8.6 Kidney Cancer survival by pathological Stage
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Testicular Cancer
There were 151 testicular cancer diagnosed  
and/or treated in SJH over the last ten years. 
Because of the demographic distribution of  
the immediate catchment area in that period, 
the number of patients presenting with testicular 
cancer and having front line treatment is relatively 
low. However, the total number also includes a 
small (n=46) but highly complex group of patients 
with high-risk relapsed or progressive testicular 
cancer. They are referred from all over the country 
for an opinion about high-dose therapy with 
autologous stem cell support in the National  
Bone Marrow transplant unit. 
These patients are currently seen by  
Dr. D. O’Donnell and Dr. P. Hayden,  
and, if, after MDT discussion, high-dose  
chemotherapy is felt appropriate, it is  
performed under the joint supervision  
of Oncology and Haematology.  
The average age at diagnosis was 33  
with a range from 15 to 78 years. 39%  
were seminoma patients.
The main survival curve (figure 8.7) includes  
only those patients (n=106) who received  
first-line treatment in SJH.
Figure 8.7 overall Testicular Cancer survival
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2.8 Haematological 
Malignancies
Introduction
The haematology department in SJH provides 
care for patients with general and malignant 
haematological disorders including leukaemia, 
myeloma and lymphoma. The service  
incorporates the National Adult Bone Marrow 
transplant unit, provides a matched unrelated 
transplant service to Northern Ireland and a 
tertiary referral for complex haematological 
malignancies to haematology colleagues in  
other units.
The service is provided in a 21 bedded dedicated 
leukaemia/bone marrow transplant unit and a 
shared day unit with medical oncology.  
A dedicated haematology/medical oncology  
ward will open in 2014. Apartments are  
provided for patients from the country following 
bone marrow transplantation by the charitable 
endeavours of the ‘Bone Marrow for Leukaemia 
Transplant’ charity.
structure
The Haematology department is part of the HOPe 
directorate chaired by Dr. Eibhlin Conneally and 
includes medical oncology, radiation oncology, 
cancer genetics, palliative care and the ‘National 
Centre for Coagulation and Haemostasis 
Disorders (NCHCD).’ The Haematology service  
is provided by Professor Paul Browne, Dr. Eibhlin 
Conneally, Dr. Catherine Flynn, Dr. Patrick Hayden 
and Professor Elizabeth Vandenberghe with a 
team of four level-3 specialist registrars, two 
registrars and three senior house officers.
The National Adult Allogeneic Bone Marrow 
transplant service under the directorship of 
Prof. P. Browne forms an integral part of 
the haematology department. Dr. Diarmaid 
O’Donghaile from the Irish Blood Transfusion 
Service provides expertise in HLA typing/
matching, specialist transfusion expertise and  
the provision of matched unrelated donors. 
The consultants provide sub-specialist service for 
leukaemias, myeloprolifertive, lymphoproliferative 
and multiple myeloma patients in designated 
specialist clinics. The lymphoma service is delivered 
by a combined haematology/oncology team. 
Access is therefore provided to an integrated 
treatment pathway for all haematology patients 
including standard chemotherapy/biological 
therapy, clinical trials and transplantation.  
There were 304 patients diagnosed with 
Haematological malignancies in 2012. 
Figure 9.1 Haematological 
malignancies 2012
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Multidisciplinary working is integral to 
haematology and includes several weekly 
multidisciplinary team meetings (MDT’s).  
These include a bone marrow transplant planning 
meeting, a Haematology MDT and a Lymphoma 
MDT. There has been a significant increase in the 
number of patients discussed at the Lymphoma 
MDT (Fig 9.2).
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Care provision is delivered in a multi-disciplinary 
setting with two bone marrow transplant  
co-ordinators, 1.4WTE (Whole Time Equivalent) 
clinical nurse specialist in post transplant 
management and 1.6 WTE clinical nurse 
specialists in haematology. 
The long term follow up (LTFU) clinic post bone 
marrow transplantation reviews patients at least 
annually and is one of the oldest services in Europe 
with patients attending since the early 1980s. 
Patients from the National Paediatric Transplant 
Service are transferred to the LTFU at SJH at 18 
years of age. Care is provided by Dr. E. Conneally, 
Dr. P. Hayden and Prof. E. Vandenberghe with 
support from a .5WTE LTFU nurse.
Dr. C. Gillham and Dr. C. O’Sullivan provide a 
radiation oncology service for the haematology, 
lymphoma and BMT service.
The haematology clinical trials service form part 
of the cancer trials office and include clinical trial 
nurses and data managers. There are 11 active 
haematology trials in progress.
The haematology laboratory (including the only 
haematological diagnostic molecular service in 
Ireland) provides an integrated diagnostic service 
to the clinical haematology service as well as 
providing a tertiary diagnostic service to other 
haematology units in Ireland; it is managed by 
Prof. E. Vandenberghe. Dr. Richard Flavin, Dr. 
Michael Jeffares and Dr. Barbara Dunne provide 
a specialist haematopathology diagnostic service. 
Dr. P. Hayden is medical director of the ‘Stem 
Cell Laboratory’ which underpins the BMT cell 
procurement and storage service under an Irish 
Medicine Board (IMB) licence.
Process
Patients attend the out patient and day service 
in the Haematology Oncology daycare centre 
(HODC) with attendances increasing year on year. 
In 2012 a total of 11884 patients attended the 
HODC, which equates to a 50% increase in day 
case activity in the past 10 years (figure 9.3).
Figure 9.2 lymphoma mdT conference (patients reviewed)
0
100
200
300
400
500
20122011201020092008200720062005
Year
 2005 2006 2007 2008 2009 2010 2011 2012
 177 229 214 267 228 388 387 429Lymphoma MDT 
84
0
2000
4000
6000
8000
10000
12000
2012201120102009200820072006200520042003
Year
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
 5910 6122 6927 8871 8964 9614 9870 11068 10770 11884Day Cases 
• Weekly consultant delivered counselling clinics 
are provided for all haematology patients 
being considered for transplantation, clinical 
trials or with complex diagnostic/management 
requirements. A donor clinic runs weekly 
for the assessment of family donors and for 
matched unrelated donors (in conjunction  
with the Irish Blood Transfusion Service (IBTS).
• Five weekly consultant-led and disease specific 
clinics are provided weekly for patients post 
transplant or on active treatment for their 
haematological malignancy. 
• Two weekly haematology clinics are provided 
for the follow-up and management of patients 
who have completed treatment.
• Three weekly consultant delivered LTFU clinics 
provide ongoing care with 686 attendances 
in 2012. This LTFU service has built up 
relationships with specialists in SJH who  
provide specialist input for this group of 
patients (Dr. Maire-Louise Healy, endocrinology, 
Dr. Ruairi Fahy, respiratory medicine, Professor 
Bernard Walsh, bone health and Dr. Ross 
Murphy, cardiology) and liaise with local 
haematology services to ensure optimal care  
for this complex group of patients. 
• The day unit staffed by clinical nurse 
managers ensure delivery of chemotherapy, 
blood products and assessment of patients 
undergoing treatment in a dedicated day unit 
with access to isolation facilities. 
BMT Unit 
The BMT unit is licensed by the IMB, accredited 
with the European Blood and Marrow Transplant 
(EBMT) European and International registry 
and is working towards JACIE accreditation in 
2015. All outcome data is provided to the EBMT 
to be bench-marked and is commensurate 
with European and International outcomes. 
The consultant staff are members of specialist 
international committees on leukaemia, multiple 
myeloma, lymphoma, aplastic anaemia, chronic 
lymphocytic leukaemia and myeloproliferative 
disorders and the late effects of BMT, thus 
ensuring that practise remains current.
The total volume of stem cell transplants carried 
out within our BMT unit has grown substantially 
(figure 9.4) in the past 10 years with a 60% 
increase in activity. This increase in transplant 
activity is in line with the Haematology department 
which has seen large growth in activity over the 
past 10 years. 
Figure 9.3 day Care attendances
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With advances in treatment and increased activity in the haematology department the diseases now 
considered for transplant has also grown. The department carries out Autologous and Allogeneic stem 
cell transplants for a very wide range of Haematological malignancies.
Figure 9.5 allogeneic Transplants disease Type
Figure 9.6 autologous Transplants disease Type
Figure 9.4 autologous and allogeneic Transplants
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SJH is the national centre for allogeneic stem cell and also performs transplant and as a result receives a 
large number of referrals for transplant and other specialist treatments. SJH is the only adult allogeneic 
transplant hospital and performs about 70% of all autologous transplants in Ireland. Many patients will 
have complex management pathways defined at SJH and then will deliver management in a shared 
approach with referring hospitals so that some elements of care can be delivered locally to the patient 
with the more intensive elements delivered at SJH (figure 9.7). In 2012 over 50% of SJH Haematology 
patients were referred from other hospitals in Ireland. 
Figure 9.7 referring Centres to SJH 2012
Survival analysis has been carried out on all patients treated with an allogeneic or autologous bone 
marrow transplant SJH over the past 5 years. The 5 year survival rate for all patients treated with  
an allogeneic transplant is 49%, and 60% for all patients treated with an autologous transplant.  
The results are illustrated in the following curves.
Figure 9.8 Five year survival post allogeneic transplant
Figure 9.9 Five year survival post autologous transplant
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2.9 Breast Cancer
summary Points
St. James’s Hospital Breast Unit was designated 
as one of the eight specialist centres for 
Symptomatic Breast Disease Services in Ireland  
by the NCCP in 2007. This has led to an increase 
in our catchment area size and has resulted in  
a large increase in referrals into the service over  
the past number of years.
The Breast Care Unit at SJH provides services 
to patients with symptomatic breast disease, 
including breast cancer. The specialist breast MDT 
includes surgeons, radiologists, pathologists, 
medical oncologists and specialised breast 
care nurses. This team work together in order 
to ensure patients are seen and investigated 
promptly and once diagnosed, receive the  
highest quality of individually planned treatment 
and care. As well as the Symptomatic breast 
service the Breast Care unit in SJH provides a  
high risk screening breast clinic to women at 
increased risk of breast cancer either due to 
a family history of this disease or other such 
risk factors e.g. previous high dose radiation 
exposure. This high risk Clinic involves using 
scoring systems based on their family history 
to identify those who require intensive breast 
surveillance and or genetic testing which can  
be done on site by Dr. David Gallagher. 
Depending on the level of risk identified 
these patients are entered into a screening 
programme using a combination of clinical exam, 
Mammogram and with the addition of breast 
MRI in those with identified high risk mutations 
e.g. BRCA1/BRCA 2 gene or equivalent risk. 
We also discuss the option of prophylactic 
mastectomy and immediate reconstruction with 
the gene positive women. There is a high risk 
breast cancer MDT run monthly which includes 
surgeons, radiologists, a geneticist, genetic nurse 
counsellors and breast care nursing team.
structure
SJH Breast Service includes:
• Consultant led triple assessment, review clinics 
and family risk clinics.
• Prompt access to all required diagnosis services 
and treatments.
• A team of specialist breast care nurses who 
attend all the clinics and are available to answer 
patient queries or concerns directly.
• Weekly MDT meetings, where each patient’s 
management plan is discussed and agreed.
• Monthly High risk breast cancer MDT for 
discussion of those patients with strong family 
histories of breast cancer.
• Direct referral service to specialist medical 
oncologists, radiation oncologists, breast 
reconstructive surgeons, specialist genetic service 
and a well established psycho-oncology service.
• Access to a range of physical and psychological 
support services.
• Dedicated genetic risk assessment and 
counselling service.
Breast Care Trends
This report examines the details of 1980 patients 
with breast cancer managed at SJH from 2003 to 
2012. On average, 2700 women are diagnosed 
with breast cancer annually. SJH manages over 
10% of the national breast cancer workload. 
Figure 10.1 illustrates breast clinic activity by year 
at SJH over this ten year period. There has been  
a 572% increase in clinic activity over the last  
ten years.
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Figure 10.2 illustrates breast cancer activity by 
year at SJH over this time period. There has  
been a 35% increase in cancer activity during  
this period of time.
When analysing data from SJH Breast Care 
department, it is clear to see the upward trend 
in both breast clinic activity and breast cancer 
diagnosis. A drop in breast cancer numbers for 
the years 2004 to 2006 is a reflection of the 
introduction of Breastcheck, the national breast-
screening programme for all women between 
the ages of 50 to 64 years. However since the 
reconfiguration of breast cancer services in 2007 
it is evident that SJH Breast Care department is 
experiencing a dramatic increase in its patient 
activity as demonstrated in figures 10.1 and 10.2.
Figure 10.1 St James’s Hospital Breast Clinic activity 2003-2012
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Figure 10.2 St James’s Hospital Breast Cancer activity 2003-2012
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Figure 10.3 Family risk Clinic activity
*Please note figures for 2013 are projected figures based on data  
for the first nine of 2013
Figure 10.3 shows the increase in activity in the 
family risk clinics since 2010 to present. Currently 
we have over 1740 patients on our family risk 
database which contains information on patients 
seen in this clinic over the last two years. Over 740 
of these are in the high risk category with 152 
identified BRCA carriers. Over the last two years 
for every 1000 women seen in this clinic, 17 screen 
detected breast cancers have been detected.
Breast cancer referral lead times
• Lead times have been reported to NCCP as 
part of their Key Performance Indicator (KPI) 
program for symptomatic breast clinics  
since 2010. 
• 100% of urgent new patients are reviewed  
in the Triple Assessment Breast Clinic within  
10 working of receipt of referral. 
• 100% of semi-urgent new patients are 
reviewed in the Triple Assessment Breast  
Clinic within 6 weeks of receipt of referral. 
• 100% of non-urgent patients are reviewed  
in a routine review breast clinic within 12 weeks 
of receipt of referral. 
• 100% of patients diagnosed with breast cancer 
in SJH are discussed at a MDT meeting. 
Gender and age analysis
Gender analysis of our patients revealed the 
breast cancer incidence to be 99.3% female 
(0.7% male). The mean patient age at diagnosis 
was 59 years. The age at diagnosis ranged from 
19 to 99 years. 36% of patients diagnosed in SJH 
were younger than 50. 
Table 10.1 age breakdown of breast 
cancer patients
age range occurrences Percent
Younger than 50 712 36
50-65 542 27.4
Older than 65 724 36.4
surgery 
Table 10.2 shows the changing trend in breast 
cancer surgery over the 10 year period, with a move 
toward breast conserving surgery and sentinel node 
biopsy as primary surgical therapy. We can also 
see an increase in immediate reconstruction and 
neoadjuvant therapy prior to surgery. 
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Tumour site and Morphology
The most common tumour site occurrence was the 
upper outer quadrant of the breast, accounting 
for 44% of breast cancer sites. Invasive ductal 
carcinoma is the most common morphology, 
accounting for 72% of all breast cancers.
Pathological staging 
Table 10.3 illustrates the breakdown by 
pathological stage for all breast cancers.
Table 10.3 Breast cancer pathology stage
T stage n stage M stage
T0 1.60% N0 54.8% M0 91%
Tis 7.80% N1 26.2% M1 9%
T1 41.15% N2 10.6%
T2 41.15% N3 8.4%
T3 6.30%
T4 2.00%
Breast Cancer research
The department of surgery breast cancer research 
group is headed by Ms. Elizabeth Connolly 
(Consultant Breast Surgeon and Associate 
Professor) and comprises a multidisciplinary 
group of surgeons, scientists, radiologists, 
pathologists, research physiotherapists and data 
managers. Research strands in the group include 
investigating the molecular events involved 
in driving the development and progression 
of breast cancer in the context of obesity and 
the metabolic syndrome. Of particular interest 
is the role of mammary adipose tissue in the 
initiation and progression of this disease. In 
addition, members of the group are prospectively 
investigating predictive and modifiable risk 
factors for the development of breast cancer in a 
cohort of BRCA mutation carriers. This ongoing 
study aims to prospectively evaluate how lifestyle 
factors such as body composition physical activity 
and diet can impact breast cancer susceptibility in 
unaffected BRCA mutation carriers. This project 
will also examine the effect of these lifestyle 
factors on telomere length and DNA damage in 
this patient cohort. Further research themes in the 
group include pre-clinical evaluation of novel drugs, 
with a particular emphasis on testing the efficacy of 
novel anti-angiogenic agents using cell line, tumour 
explant and in vivo models of breast cancer. Central 
to our research, we maintain a breast cancer blood 
and tissue biobank of high quality samples linked 
to up to date clinical information. This biobank 
provides us with the patient material necessary to 
meet our research objectives.
Table 10.2 age breakdown of breast cancer patients
year surgery
Primary 
Breast
Conserving
surgery1,2
Primary 
Mastectomy
Mastectomy 
with 
Immediate 
reconstruction 
Primary 
axillary 
Clearance3 
Primary 
sentinel 
node 
Biopsy
neoadjuvant 
treatment 
prior to 
surgery
2003 176 39.7% 60.30% 0.0% 92.6% 0.0% 4.5%
2004 116 35.3% 64.6% 0.0% 98.3% 0.0% 9.5%
2005 114 45.6% 54.4% 0.0% 92.1% 7.9% 1.8%
2006 107 54.2% 45.8% 0.0% 54.2% 36.4% 5.6%
2007 135 63.0% 37.0% 0.0% 34.1% 62.2% 1.5%
2008 124 56.5% 40.3% 3.2% 28.2% 67.0% 4.8%
2009 168 59.0% 38.7% 2.3% 32.1% 61.3% 14.3%
2010 228 60.1% 35.5% 4.4% 28.5% 66.2% 11.0%
2011 233 65.2% 29.2% 4.3% 26.2% 70.8% 19.3%
2012 207 62.8% 31.4% 5.8% 27.1% 68.6% 25.6%
1. 3 patients over the 10 years had bilateral surgery, both breast conserving and mastectomy. 2. 6 patients had surgical therapy other than breast 
conserving and mastectomy such as breast reduction surgery, excision of node in previous mastectomy scar, etc. 3. Not all surgical patients receive 
axillary dissection.
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survival analysis
Figure 10.4 overall Breast cancer survival
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Figure 10.5 Breast Cancer survival by pathological Stage
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Appendix 1 Methods
sources of Data
All information is actively obtained and audited 
by the cancer data managers with the clinicians 
and nursing staff ongoing input on all patients 
diagnosed and treated with cancer in SJH.
Data acquisition is obtained from the following 
sources:
• SJH Patient Administration System (PAS)
• SJH Pathology system
• SJH theatre management system
• SJH EPR system
• HIPE Data from www.esri.ie HIPE data was 
provided by staff from the HIPE coding 
department in SJH. Patient with ICD 9 codes 
between 140 and 239.9 were included until 
December 2005. From January 2006, ICD 10 
codes between C00-D48 replaced ICD9 codes. 
ICD codes D10-D36 are excluded.
• MDT meetings. 
• SJH Endoscopy system
• Services for death registration information. 
www.groireland.ie 
• GP
• Chemotherapy recording system SJH
• NCRI
• Radiotherapy information from SLRON
recording of Data
The cancer audit programme has been in place in 
SJH for over 10 years. Since 2001, an electronic 
cancer information system has replaced a paper 
system. The information system (PATS – software 
by Dendrite Clinical Systems) is divided into 16 
cancer registries that are managed and audited by 
a data manager. There are other small registries 
that complement these include rapid access clinic 
registries.
Each registry has a core set of data items 
that captures key SJH cancer information 
requirements, the NCRI minimum dataset 
and incorporates site-specific national and 
international cancer and clinical datasets. 
Modifications have included capture of KPI  
data from the NCCP. 
Patient information is captured from time of 
referral through follow-up and to time of death 
or last follow-up. The data managers ensure that 
follow-up is as up to date as possible to facilitate 
accurate survival analysis.
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Data analysis
All basic calculations have been completed by 
PATS, i.e. tabulation of the data. All survival 
curves were generated by a statistical software 
package, Stata (version 10.1). Survival analysis 
was generated using the Kaplein Meier method. 
Overall survival was used in the calculation of 
survival, unless otherwise stated and cancer 
free survival was used. A chi-square analysis 
test was used to investigate the comparisons of 
demographical factors in section one.
Data Quality
One of our constant key priorities of the cancer 
audit team has been the continuous improvement 
of QA initiatives to ensure the accurate and 
timely information is available to clinicians and 
management to measure the quality of care 
received by cancer patients in SJH.
There are two mechanisms for quality control and 
validation of our data. Continuous data quality 
checks at the time of data capture and periodical 
reviews of the accuracy and validity of our data.
All data managers complete regular QA, error 
and completeness checks across all registries 
across the entire data collection process. The 
PATS software system allows the facility to control 
user access and privilege. There is an audit trail 
facility to track data entry by all users. The system 
restricts users to a range of predetermined values 
for each data item, and checks for internal 
consistency. 
Monthly and annual audits of all information 
are routinely done and presented to clinicians to 
review. Lead clinicians are ultimately responsible 
for data produced.
The introduction of collaborative quality 
improvement programmes (QIP) in each of the 
individual tumour sites has been significant in 
improving the validation and quality control of our 
data. These QIP groups meet regularly and data 
is can be prospectively measured, assessed, and 
benchmarked against national and international 
performance indicators.
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Appendix 2 Cancer Audit 
Programme Team
Professor John Reynolds Cancer Audit Lead reynoldspa@stjames.ie
Ms. Suzanne Rowley Cancer Audit Manager srowley@stjames.ie
Ms. Charlotte Stuart Colorectal Cancer Data Manager cstuart@stjames.ie
Ms. Kerena Sutcliffe Lung Cancer Data Manager ksutcliffe@stjames.ie
Ms. Sinead King Upper GI & Hepatobilary Data Manager sking@stjames.ie
Ms. Lorraine Quinn Breast Cancer Data Manager lquinn@stjames.ie
Mr. Richard Lawson Haematology Data Manager rlawson@stjames.ie
Ms. Mary Devlin Head & Neck Cancer Data Manager mdevlin@stjames.ie
Ms. Therese Brown Gynaecological Cancer Data Manager tbrown@stjames.ie
Ms. Avril Nolan Breast Data Clerk anolan@stjames.ie
Left to right. Lorraine Quinn, Sinead King, Suzanne Rowley, Prof. John Reynolds, Charlotte Stuart,  
Mary Devlin, Richard Lawson, Kerena Sutcliffe.
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Appendix 5 Abbreviations
aCPGBI Association of Coloproctology of Great Britain & Ireland
all  Acute Lymphocytic Leukemia
aMl  Acute Myelogenous Leukemia
aMnCH  Adelaide & Meath Hospital, Incorporating the National's Children's Hospital Tallaght)
aPer  Abdomino-Perineal Excision of the rectum
asCo  American Society of Clinical Oncology
nCMG  National Centre for Medical Genetics
nM  Nuclear Medicine
BCC  Basal Cell Carcinoma
BMT  Bone Barrow Transplant
BraF  Proto-oncogene B-Raf
BToG  British Thoracic Oncology Group
CaCT  Centre for Advances in Clinical Therapeutics
CaMI  Centre of Advanced Medical Imaging
CaP  Cancer Audit Programme
CCTo  Cancer Clinical Trials Office
Ceo  Chief Executive Officer
CGMP  Current Good Manufacturing Practice
CIrG  Cancer International Research Group
ClD  Centre for Learning & Development
Cll  Chronic Lymphocytic Leukaemia
CMD  Cancer Molecular Diagnostics
CnM  Clinical Nurse Manager
CrC  Colorectal Cancer
Cns  Clinical Nurse Specialist
Crann  Centre for Research on Adaptive Nanostructures and Nano Devices
CrC  Colorectal cancer
CT  Computed Topography
CwIUH  Coombe Women’s  & Infant’s University Hospital
DCU  Dublin City University
DCCr  Dublin Centre for Clinical Research
DDH  Dublin Dental Hospital
DDs  Dublin Dental School
DlBCl  Diffuse Large B-Cell Lymphoma
Dna  Deoxyribonucleic Acid
eBMT  European Bone Marrow Transplant
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eBUs  Endo Bronchial Ultrasound
eCoG  Eastern Cooperative Oncology Group
eGFr  Epidermal Growth Factor Receptor
eMBraCe  Epidemiology Study of Familial Breast Cancer 
eMr  Endo Mucosal Resection
eorTC  European Organisation for Research & Treatment of Cancer
ePr  Electronic Patient Record
eras  Enhanced recovery After Surgery
erHa  Eastern region health Authority
enT  Ear, Nose and Throat
esTro  European Society for Therapeutic Radiology and Oncology
eU  European Union
eUs  Endoscopic Ultrasound
FDa  Food and Drug Administration
Fees  Fiberoptic Endoscopic Examination of Swallowing
GCP  Good Clinical Practice
GeMs  Directorate: GI Medicine & Surgery, General Medicine Inc Hepatology & Urology
GCIG  Gynaecologic Cancer Intergroup
GP  General Practitioner
HDU  High Dependency Unit
HIPe  Hospital Inpatient Enquiry
HIQa  Health Information and Quality Authority
Hl  Hodgkin’s Lymphoma
HnPCC  Hereditary Non Polyposis Colorectal Cancer
HoDC  Haematology Oncology Day Care
HoPe  Haematology Oncology, Medical & Radiation Oncology & Palliative Care
HrB  Health Research Board
HsCT  Haematopoietic Stem Cell Transplantation
Hse  Health Service Executive
IBMTr  International Bone Marrow Transplant Registry
Iasw  Irish Association of Social Workers
IBTs  Irish Blood Transfusion Service
ICD  International Classification of Disease
ICU  Intensive Care Unit
ICorG  Irish Clinical Oncology Research Group
ICs  Irish Cancer Society
Kras V-Ki-ras2  Kirsten rat sarcoma viral oncogene
IMB  Irish Medicines Board
IMrT  Intensity Modulated Radiation Therapy
IMs  Information Management Services
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JaCIe  The Joint Accreditation Committee-ISCT (Europe)
KPI  Key Performance Indicator
la  Linear Accelerator
lTFU  Long Term Follow Up
MDT  Multidisciplinary Team
MIra Mercers Institute for Research on Ageing
MPBe  Medical Physics and Bioengineering
MMs  Moh’s Microsurgical Unit
MrI  Magnetic Resonance Imaging
nBMTU  National Cancer Bone Marrow Transplant Unit
nCCP  National cancer Control Programme
nMsC  Non Melanoma Skin Cancer
nCHCD  National Centre for Coagulation and Haemostasis Disorders
nCI  National Cancer Institute, Washington 
nCrI  National Cancer Registry of Ireland
nHs  National Health Service
nIMIs  National Integrated Medical Imaging System
nICe  National Institute for Health & Clinical Excellence
nMsC  Non Melanoma Skin Cancer
nsaPB  National Surgery Adjuvant Breast & Bowel Group
olH  Our Lady’s Hospice
olH&Cs  Our Lady’s Hospice and Care Services
olHsC  Our Lady’s Hospital for Sick Children
oP  Occupational Therapy
QIP  Quality Improvement Programme
PaCs  Picture Archiving and Communication System
PaTs  Patient Analysis & Tracking System
Pas  Patient Administration System
PeT  Positron Emission Tomography
PI  Principal Investigator
QaQT  Quality Assurance Quality Control
raPC  Rapid Access Prostate Clinic
rCoG  Royal Society of Gynaecologists
rCsI  Royal College of Surgeons in Ireland
rFMa  Radiofrequency and Microwave Ablation
rna  Ribonucleic acid
saMs  Dermatology, Endocrinology, GUIDE, Gynaecology, Neurology, Opthamology % Rheumatology
sCoPe  Speech & Language Therapy, Medical Socia Work, Clinical Nutririon,  
 Occupational Therapy & Physiotherapy
sJH  St James’s Hospital
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slH  St. Luke’s Hospital
slroC  St Luke’s Radiation Oncology Centre
slron  St Luke’s Radiation Oncology Network
slT  Speech & Language Therapy
snB  Sentinel Node Biopsy
sPD  Sir Patrick Duns
sPeCT  Single-Photon Emission Computed Tomography
TBI  Total Body Irradiation
TBna  Trans Bronchial Needle Aspirate
TCBe  Trinity Centre for Bioengineering
TCD  Trinity College Dublin
TBsI  Trinity Biomedical Sciences Institute
TCIn  Trinity College Institute of Neurosciences
THI  Trinity Health Ireland
TTMI  Trinity Translational Medicine Institute
TUrP  Transurethral Resection of Prostate
Us  Ultrasound
wTe  Whole Time Equivalent
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Ms. elaine Dunne HIPE Manager, SJH
Ms. Fiona Dwane Data Manager, NCRI
Mr. anthony edwards Clinical Photographer, SJH
Mr. Barry Fanning IMS, SJH
Mr. David Farrell MDT Co-ordinator
Dr. David Gallagher Genetics Consultant
Dr. noreen Gleeson Consultant Gyanecologist
HIPe Unit www.esri.ie
Ms. elaine Jackson HIPE Unit, SJH
Prof John Kennedy Consultant Medical Oncologist
Ms. Ingrid Kiernan CCTO
Dr. niamh leonard Consultant Histopathologist
Prof Thomas lynch Urology Surgeon
Mr. rustom Manecksha Urology Surgeon
Mr. Paul McCormick Colorectal Surgeon
Ms.  sarah McGarrigle Biobank Manager, TCD
Mr. Brian Mehigan Colorectal Surgeon
Ms. niamh Murphy SCOPe Manager
Ms. Deirdre Murray NCCP
Ms. Carmel nolan Genetics Nurse
Ms. siobhan nunn Principal Medical Social Worker, SJH
Dr. Finbarr o'Connell Clinical Director and Respiratory 
Consultant
Dr. Hugh o'Connor Consultant Gynaecologist
Dr. Dearbhaile o'Donnell Consultant Medical Oncologist
Dr. rory o'Donnell Respiratory Consultant
Ms. Gina o'Donoghue Speech and Language Therapy 
Head
Dr. ann Marie o'Dwyer Psychological Medicine
Ms. aoife o’Gorman Occupational Therapy Manager
Dr. norma o'leary Palliative Care Consultant
Ms. Jacinta o’sullivan Senior Lecturer, TCD
Dr. Patrick ormond Consultant Dermatologist
Mr. ronan ryan Consultant Cardiothoracic Surgeon
Mr. narayanasamy ravi Upper GI Surgeon
Ms. shona schneeman HOPE Business Manager
Dr. niall sheehy Consultant Radiologist
Prof leo stassen Maxillo Facial Surgeon
Ms. ann Tierney MDT Co-ordinator
Prof Conrad Timon Consultant Head and Neck Surgeon
Dr. elizabeth Vandenberghe Consultant Haematologist
Mr. Vincent young Consultant Cardiothoracic Surgeon
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The Hospital’s fundamental purpose is the delivery of health treatment, care and diagnosis as well as  
health promotion and preventative services at catchment, regional, supra-regional and national levels.
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